



HU000025604T2

(19) **HU**(11) Lajstromszám: **E 025 604**(13) **T2****MAGYARORSZÁG**  
Szellemi Tulajdon Nemzeti Hivatala**EURÓPAI SZABADALOM**  
**SZÖVEGÉNEK FORDÍTÁSA**(21) Magyar ügyszám: **E 10 153355**(51) Int. Cl.: **C12N 9/42** (2006.01)(22) A bejelentés napja: **2010. 02. 11.**(96) Az európai bejelentés bejelentési száma:  
**EP 20100153355**(97) Az európai bejelentés közzétételi adatai:  
**EP 2357227 A1** **2011. 08. 17.**(97) Az európai szabadalom megadásának meghirdetési adatai:  
**EP 2357227 B1** **2015. 07. 15.**

(72) Feltaláló(k):  
**Reisinger, Christoph, Dr., 81477 München (DE)**  
**Brück, Thomas, Dr., 82067 Ebenhausen (DE)**  
**Koltermann, André, Dr., 82057 Icking (DE)**  
**Gerlach, Jochen, Dr., 80687 München (DE)**  
**Unterstrasser, Isabel, 83253 Rimsting (DE)**  
**Röcher, Lutz, 81541 München (DE)**  
**Rarbach, Markus, Dr., 81369 München (DE)**  
**Claren, Jörg, Dr., 81476 München (DE)**  
**Kohl, Andreas, Dr., 81369 München (DE)**  
**Pieck, Jan, Carsten, Dr., 80689 München (DE)**  
**Schlosser, Dominik, 81369 München (DE)**

(73) Jogosult(ak):  
**Süd-Chemie IP GmbH & Co. KG, 80333**  
**München (DE)**

(74) Képviselő:  
**Kovári György, ADVOPATENT Szabadalmi**  
**Iroda, Budapest**

(54)

**Optimalizált cellulóz enzimek**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 357 227 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**15.07.2015 Bulletin 2015/29**

(51) Int Cl.:  
**C12N 9/42 (2006.01)**

(21) Application number: **10153355.2**

(22) Date of filing: **11.02.2010**

(54) **Optimized cellulase enzymes**

Optimierte Zellulaseenzyme

Enzymes de cellulase optimisées

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR**

(43) Date of publication of application:  
**17.08.2011 Bulletin 2011/33**

(73) Proprietor: **Süd-Chemie IP GmbH & Co. KG**  
**80333 München (DE)**

- (72) Inventors:
- **Reisinger, Christoph, Dr.**  
**81477 München (DE)**
  - **Brück, Thomas, Dr.**  
**82067 Ebenhausen (DE)**
  - **Koltermann, André, Dr.**  
**82057 Icking (DE)**
  - **Gerlach, Jochen, Dr.**  
**80687 München (DE)**
  - **Unterstrasser, Isabel**  
**83253 Rimsting (DE)**
  - **Röcher, Lutz**  
**81541 München (DE)**
  - **Rarbach, Markus, Dr.**  
**81369 München (DE)**
  - **Claren, Jörg, Dr.**  
**81476 München (DE)**
  - **Kohl, Andreas, Dr.**  
**81369 München (DE)**
  - **Pieck, Jan, Carsten, Dr.**  
**80689 München (DE)**
  - **Schlosser, Dominik**  
**81369 München (DE)**
  - **The other inventors have agreed to waive their entitlement to designation.**

(74) Representative: **Graser, Konstanze et al**  
**Clariant Produkte (Deutschland) GmbH**  
**Patent Management**  
**Lenbachplatz 6**  
**80333 München (DE)**

(56) References cited:  
**WO-A1-2006/117432 WO-A1-2009/139839**  
**WO-A1-2010/005553 WO-A2-2009/138877**

- **DATABASE UniProt [Online] 1 February 2005 (2005-02-01), "SubName: Full=Cellobiohydrolase;" XP002593511 retrieved from EBI accession no. UNIPROT:Q5MBA7 Database accession no. Q5MBA7**
- **DATABASE PDB [Online] 24 February 2009 (2009-02-24), Grassnick et al.: "3-DIMENSIONAL STRUCTURE OF NATIVE CEL7A FROM TALAROMYCES EMERSONII" XP002593512 retrieved from EBI accession no. PDB:1Q9H Database accession no. 1Q9H**
- **GRASSICK ALICE ET AL: "Three-dimensional structure of a thermostable native cellobiohydrolase, CBH IB, and molecular characterization of the cel7 gene from the filamentous fungus, Talaromyces emersonii", EUROPEAN JOURNAL OF BIOCHEMISTRY, GB, vol. 271, no. 22, 1 November 2004 (2004-11-01), pages 4495-4506, XP002547329, ISSN: 0014-2956, DOI: 10.1111/J.1432-1033.2004.04409.X**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 357 227 B1**

**Description****Field of invention**

5 [0001] The invention discloses cellulase enzymes with optimized properties for processing of cellulose- and lignocel-  
lulose-containing substrates. In particular, cellobiohydrolase enzymes with preferred characteristics are disclosed. The  
present disclosure provides fusion, insertion, deletion and/or substitution variants of such enzymes. Enzyme variants  
have enhanced thermostability, proteolytic stability, specific activity and/or stability at extreme pH. Nucleic acid molecules  
10 encoding said enzymes, a composition comprising said enzymes, a method for preparation, and the use for cellulose  
processing and/or for the production of biofuels are disclosed.

**Background of the invention**

15 [0002] The development of production processes based on renewable resources is highly desired, for example for  
the generation of ethanol from cellulosic and lignocellulosic materials.

[0003] Cellulose material in pure form or in combination with hemicellulose and/or lignin is a valuable and readily  
available raw material for the production of chemicals and fuels. A key step in processing cellulose and lignocellulose  
is the hydrolysis of the beta-1,4-linked glucose polymer cellulose and the subsequent release of glucose monomers and  
short glucose oligomers such as cellobiose, cellotriose, etc. Enzymes that catalyze this reaction are found in various  
20 organisms, especially filamentous fungi and bacteria, that are capable of degrading and hydrolysing cellulose.

[0004] Continuous processes for converting solid lignocellulosic biomass into combustible fuel products are known.  
Treatment to make cellulosic substrates more susceptible to enzymatic degradation comprises milling, chemical process-  
ing and/or hydrothermal processing. Examples are wet oxidation and/or steam explosion. Such treatments increase the  
accessibility of cellulose fibers and separate them from hemicellulose and lignin. required for the degradation of cellulose  
25 polymers. Among these cellobiohydrolase (CBH) enzymes, and more specifically cellobiohydrolase I (CBHI) enzymes,  
play a key role in the hydrolysis step as they provide the most processive enzymatic activity. CBHI enzymes catalyze  
the progressive hydrolytic release of cellobiose from the reducing end of the cellulose polymers. (Lynd LR, Weimer PJ,  
van Zyl WH, Pretorius IS. Microbial cellulose utilization: fundamentals and biotechnology. Microbiol Mol Biol Rev. 2002  
Sep;66(3):506-77).

30 [0005] Hydrolyzed cellulosic materials contain several valuable carbohydrate molecules which can be isolated from  
the mixtures. Sugar containing hydrolysates of cellulosic materials can be used for microbial production of a variety of  
fine chemicals or biopolymers, such as organic acids, ethanol or higher alcohols (also diols or polyols) or polyhydroxy-  
alkanoates (PHAs). One of the major uses of the sugar hydrolysates is in the production of biofuels.

[0006] Kurabi et al. (2005) describes preparations of cellulases from *Trichoderma reesei* and other fungi, such as  
35 *Penicillium* sp. The performance has been analysed on steam-exploded and ethanol organosolv-pretreated Douglas-  
fir. Better performance of enzyme mixtures appears to be a result of improved properties of single component enzymes  
as well as the effect of each compound in the mixture, especially the presence of beta-glucosidase. (Kurabi A, Berlin A,  
Gilkes N, Kilburn D, Bura R, Robinson J, Markov A, Skomarovsky A, Gusakov A, Okunev O, Sinitsyn A, Gregg D, Xie  
D, Saddler J.(2005) Enzymatic hydrolysis of steam-exploded and ethanol organosolv-pretreated Douglas-Fir by novel  
40 and commercial fungal cellulases. Appl Biochem Biotechnol.121-124: 219-30).

[0007] Cellobiohydrolase sequences of the glucohydrolase class 7 (cel7) are known to the art from several fungal  
sources. The *Talaromyces emersonii* Cel7 cellobiohydrolase is known and expression was reported in *Escherichia coli*.  
Grassick *et al.* present a report on the purification and 3D structural determination of a native core CBH protein, and of  
the cloning and over-expression of the corresponding gene, from a thermophilic fungal source. CBH 16 was found to  
45 be extremely thermostable with a temperature optimum of 68 °C at pH 5.0 and a half-life ( $t_{1/2}$ ) of 68.0 min at 80 °C and  
pH 5.0. (Grassick A, Murray PG, Thompson R, Collins CM, Byrnes L, Birrane G, Higgins TM, Tuohy MG. Three-dimen-  
sional structure of a thermostable native cellobiohydrolase, CBH 16, and molecular characterization of the cel7 gene  
from the filamentous fungus, *Talaromyces emersonii*. Eur J Biochem. 2004 Nov;271 (22):4495-4506) and *Saccharomy-  
ces cerevisiae* (Voutilainen SP, Murray PG, Tuohy MG, Koivula A. Expression of *Talaromyces emersonii* cellobiohydro-  
50 lase Cel7A in *Saccharomyces cerevisiae* and rational mutagenesis to improve its thermostability and activity. Protein  
Eng Des Sel. 2010 Feb;23(2):69-79), however the protein was either produced in inactive form or at rather low yields  
(less or equal to 5mg/l). *Hypocrea jecorina* cellobiohydrolase I can be produced from wild type or engineered strains of  
the genus *Hypocrea* or *Trichoderma* at high yields. Improved sequences of *Hypocrea jecorina* Cel7A are disclosed by  
US7459299B2, US7452707B2, WO2005/030926, WO01/04284A1 or US2009/0162916 A1.

55 [0008] Positions leading to improvements were deduced from alignments with sequences from reported thermostable  
enzymes, suggested from structural information and shuffling of identified positions followed by limited screenings.  
Screening of larger libraries in transformable organisms such as *Saccharomyces cerevisiae* was reported by application  
of very sensitive fluorescent substrates, which resemble native substrates in a very restricted way. (Percival Zhang YH,

Himmel ME, Mielenz JR. Outlook for cellulase improvement: screening and selection strategies. *Biotechnol Adv.* 2006 Sep-Oct;24(5):452-81).

**[0009]** The production of cellobiohydrolases from other fungal systems such as *Thermoascus aurantiacus*, *Chrysosporium lucknowense* or *Phanerochaete chrysosporium* was reported. Expression of Cel7 cellobiohydrolase from yeasts was reported, but enzymatic yields or enzyme properties remain unsatisfactory. (Penttilä ME, André L, Lehtovaara P, Bailey M, Teeri TT, Knowles JK. Efficient secretion of two fungal cellobiohydrolases by *Saccharomyces cerevisiae*. *Gene.* 1988;63(1):103-12).

**[0010]** WO03/000941 discloses a number of CBHs and their corresponding gene sequences. Physiological properties and applications however were not disclosed. The fusion of cellulose binding domains to catalytic subunits of cellobiohydrolases is reported to improve the hydrolytic properties of proteins without a native domain.

**[0011]** US 2009042266 (A1) discloses fusions of *Thermoascus aurantiacus* Cel7A with cellulose binding domains from cellobiohydrolase I from *Chaetomium thermophilum* and *Hypocrea jecorina*.

**[0012]** US5686593 reports the fusion of specially designed linker regions and binding domains to cellobiohydrolases.

**[0013]** **Hong et al. (2003)** describe the production of *Thermoascus aurantiacus* CBHI in yeast and its characterization. (Hong J, Tamaki H, Yamamoto K, Kumagai H Cloning of a gene encoding thermostable cellobiohydrolase from *Thermoascus aurantiacus* and its expression in yeast. *Appl Microbiol Biotechnol.* 2003 Nov;63(1):42-50).

**[0014]** **Tuohy et al. (2002)** report the expression and characterization of *Talaromyces emersonii* CBH. (Tuohy MG, Walsh DJ, Murray PG, Claeysens M, Cuffe MM, Savage AV, Coughlan MP. Kinetic parameters and mode of action of the cellobiohydrolases produced by *Talaromyces emersonii*. *Biochim Biophys Acta.* 2002 Apr 29;1596(2):366-80).

**[0015]** **Nevoigt et al. (2008)** reports on the expression of cellulolytic enzymes in yeasts. (Nevoigt E. Progress in metabolic engineering of *Saccharomyces cerevisiae*. *Microbiol Mol Biol Rev.* 2008 Sep;72(3):379-412).

**[0016]** **Fujita et al. (2004)** reports on a *Saccharomyces cerevisiae* strain expressing a combination of an endoglucanase, a beta glucosidase and a CBHI displayed on the cell surface. Cellobiohydrolase I (Cel7) was not used in this setup. (Fujita Y, Ito J, Ueda M, Fukuda H, Kondo A. Synergistic saccharification, and direct fermentation to ethanol, of amorphous cellulose by use of an engineered yeast strain codisplaying three types of cellulolytic enzyme. *Appl Environ Microbiol.* 2004 Feb;70(2):1207-12).

**[0017]** **Boer H et al. (2000)** describes the expression of GH7 classified enzymes in different yeast hosts but expressed protein levels were low. (Boer H, Teeri TT, Koivula A. Characterization of *Trichoderma reesei* cellobiohydrolase Cel7A secreted from *Pichia pastoris* using two different promoters. *Biotechnol Bioeng.* 2000 Sep 5;69(5):486-94).

**[0018]** **Godbole et al (1999)** and **Hong et al (2003)** found that proteins of this enzyme class expressed from yeast were often misfolded, hyperglycosylated and hydrolytic capabilities decreased compared to the protein expressed from the homologous host. (Godbole S, Decker SR, Nieves RA, Adney WS, Vinzant TB, Baker JO, Thomas SR, Himmel ME. Cloning and expression of *Trichoderma reesei* cellobiohydrolase I in *Pichia pastoris*. *Biotechnol Prog.* 1999 Sep-Oct;15(5):828-33).

**[0019]** **Kanokratana et al (2008)**, **Li et al (2009)** as well as CN01757710 describe the efficient expression of Cel7 CBH I enzymes, however these proteins are lacking cellulose binding domains required for efficient substrate processing. (Kanokratana P, Chantasingh D, Champreda V, Tanapongpipat S, Pootanakit K, Eurwilaichitr L Identification and expression of cellobiohydrolase (CBHI) gene from an endophytic fungus, *Fusicoccus* sp. (BCC4124) in *Pichia pastoris*. *LProtein Expr Purif.* 2008 Mar;58(1):148-53. Epub 2007 Sep 19; Li YL, Li H, Li AN, Li DC. Cloning of a gene encoding thermostable cellobiohydrolase from the thermophilic fungus *Chaetomium thermophilum* and its expression in *Pichia pastoris*. *J Appl Microbiol.* 2009 Jun;106(6):1867-75).

**[0020]** **Voutilainen (2008)** and **Viikari (2007)** disclose Cel7 enzymes comprising thermostable cellobiohydrolases, however with only low to moderate expression levels from *Trichoderma reesei*, (Voutilainen SP, Puranen T, Siika-Aho M, Lappalainen A, Alapuranen M, Kallio J, Hooman S, Viikari L, Vehmaanperä J, Koivula A. Cloning, expression, and characterization of novel thermostable family 7 cellobiohydrolases. *Biotechnol Bioeng.* 2008 Oct 15;101(3):515-28. PubMed PMID: 18512263; Viikari L, Alapuranen M, Puranen T, Vehmaanperä J, Siika-Aho M. Thermostable enzymes in lignocellulose hydrolysis. *Adv Biochem Eng Biotechnol.* 2007;108:121-45).

**[0021]** **Grassick et al. (2004)** disclose unfolded expression of Cellobiohydrolase I from *Talaromyces emersonii* in *Escherichia coli* but not in yeast. (Grassick A, Murray PG, Thompson R, Collins CM, Byrnes L, Birrane G, Higgins TM, Tuohy MG. Three-dimensional structure of a thermostable native cellobiohydrolase, CBH IB, and molecular characterization of the cel7 gene from the filamentous fungus, *Talaromyces emersonii*. *Eur J Biochem.* 2004 Nov;271(22):4495-506).

**[0022]** WO 2009/138877 describes a method for heterologous expression of polypeptides encoded by wild-type and codon-optimized variants of cbh1 and/or cbh2 from the fungal organisms *Talaromyces emersonii* (*T. emersonii*), *Humicola grisea* (*H. grisea*), *Thermoascus aurantiacus* (*T. aurantiacus*), and *Trichoderma reesei* (*T. reesei*) in host cells, such as the yeast *Saccharomyces cerevisiae*. The expression in such host cells of the corresponding genes, and variants and combinations thereof, were found to result in improved specific activity of the expressed cellobiohydrolases.

**[0023]** WO 2009/139839 describes a methods and composition for a large capacity alphavirus vector and particle. In

some aspects methods for providing alphavirus particles comprising a modified capsid protein are described.

**[0024]** Therefore, there is a need for cellulase enzymes with improved characteristics for the use in technical processes for cellulose hydrolysis. In particular there is a need for CBH enzymes with higher catalytic activity and/or higher stability under process conditions. Moreover there is a need for CBH enzymes with higher productivity in fungal and/or yeast expression and secretion systems.

### Summary of the invention

**[0025]** The present invention provides a polypeptide having cellobiohydrolase activity. This polypeptide comprises an amino acid sequence having at least 85 % sequence identity to SEQ ID NO: 2, wherein the amino acid residue at position Q1 of SEQ ID NO: 2 is modified by substitution or deletion.

**[0026]** Furthermore, the present invention discloses a nucleic acid encoding the polypeptide of the present invention, preferably having at least 95 % identity to SEQ ID NO: 1, a vector comprising this nucleic acid and a host transformed with said vector.

**[0027]** The present application further discloses a method of producing a cellobiohydrolase protein encoded by a vector of the present invention, a method for identifying polypeptides having cellobiohydrolase activity, and a method of preparing such polypeptides having cellobiohydrolase activity.

**[0028]** The present invention also provides a polypeptide having cellobiohydrolase activity, wherein the polypeptide comprises an amino acid sequence having at least 85 % sequence identity to SEQ ID NO: 2, wherein the amino acid residue at position Q1 of SEQ ID NO: 2 is modified by substitution or deletion, wherein one or more of the following amino acid residues of the sequence defined by SEQ ID NO: 2 are modified by substitution or deletion: G4, A6, T15, Q28, W40, D64, E65, A72, S86, K92, V130, V152, Y155, K159, D181, E183, N194, D202, P224, T243, Y244, I277, K304, N310, S311, N318, D320, T335, T344, D346, Q349, A358, Y374, A375, T392, T393, D410, Y422, P442, N445, R446, T456, S460, P462, G463, H468 and/or V482 of amino acids 1 to 500 of SEQ ID NO: 2.

**[0029]** Moreover, the present application discloses a polypeptide having cellobiohydrolase activity, which is obtainable by the method of preparing a polypeptide having cellobiohydrolase activity according to the present application, and a polypeptide having cellobiohydrolase activity, wherein the polypeptide comprises an amino acid sequence having at least 80 % sequence identity to SEQ ID NO: 5, wherein one or more of the following amino acid residues of the sequence defined by SEQ ID NO: 5 are modified by substitution or deletion: Q1, G4, A6, T15, Q28, W40, D64, E65, A72, S86, K92, V130, V152, Y155, K159, D181, E183, N194, D202, P224, T243, Y244, I277, K304, N310, S311, N318, D320, T335, T344, D346, Q349, A358, Y374, A375, T392, T393, D410 and/or Y422 of amino acids 1 to 440 of SEQ ID NO: 5.

**[0030]** The present application furthermore discloses a polypeptide having cellobiohydrolase activity comprising an amino acid sequence having at least 85 % sequence identity to SEQ ID NO: 12 wherein one or more of the following amino acid residues of the sequence defined by SEQ ID NO: 12 are modified by substitution or deletion: Q1, T15, Q28, W40, C72, V133, V155, Y158, T162, Y247, N307, G308, E317, S341, D345, Y370, T389, Q406, N441, R442, T452, S456, P458, G459, H464 and/or V478.

**[0031]** The present invention furthermore discloses a composition comprising a polypeptide of the present invention and one or more endoglucanases and/or one or more beta-glucosidases and/or one or more further cellobiohydrolases and/or one or more xylanases.

**[0032]** The present invention further provides the use of a polypeptide or the composition of the present invention for the enzymatic degradation of lignocellulosic biomass, and/or for textiles processing and/or as ingredient in detergents and/or as ingredient in food or feed compositions.

### Brief description of the figures

#### [0033]

Figure 1: Restriction Maps of pV1 for constitutive expression of Proteins in *Pichia pastoris*: pUC19 - ori: Origin of replication in *E. coli*; KanR: Kanamycine/G418 Resistance with TEF1 and EMZ Promoter sequences for selection in *Pichia pastoris* and *E. coli*, respectively; 5'GAP: glyceraldehyde-3-phosphate dehydrogenase Promoter region; 3'-GAP: terminator region; SP MFalpha: *Saccharomyces cerevisiae* mating factor alpha signal sequence; MCS: multiple cloning site.

Figure 2: Commassie stained SDS-PAGE of 10-fold concentrated supernatants of shake-flask cultures of *Pichia pastoris* CBS 7435 containing expression plasmids with coding sequences for the mature CBHI proteins of *Trichoderma viride* (CBH-f; lane 2), *Humicola grisea* (CBH-d; lane 3), *Talaromyces emersonii* (CBH-b; lane 4), *Thermoascus aurantiacus* (CBH-e; lane 5), as well as the *Talaromyces emersonii* CBHI-CBD fusion (CBH-a; lane 6) and the *Humicola grisea*-CBD fusion (CBH-g; lane 7) in N-terminal fusion to the signal peptide of the *Saccharomyces*

## EP 2 357 227 B1

*cerevisiae* mating factor alpha under control of the *Pichia pastoris* glyceraldehyde-3-phosphate dehydrogenase promoter.

5 Figure 3: Map of the pV3 expression plasmid for protein expression in *Pichia pastoris*. Replicons: pUC19 - ori: Origin of replication in *E. coli*; ZeoR: Zeocine resistance gene with TEF1 and EM7 promoter sequences for expression in *Pichia pastoris* and *E. coli*, respectively; AOX I promoter: Promoter region of the *Pichia pastoris* alcohol oxidase I gene; AOX 1 transcriptional terminator: terminator region; SP MFalpha: *Saccharomyces cerevisiae* mating factor alpha signal sequence; MCS: multiple cloning site.

10 Figure 4: SDS-PAGE analysis of culture supernatant samples taken from the fermentation of a *Pichia pastoris* strain with a genomic integration of an AOXI-expression cassette, expressing the *Talaromyces emersonii* CBHI / *Trichoderma reesei*-CBD fusion peptide (CBH-a) in a 71 bioreactor during methanol induction. Samples P1 - P7 are taken at the beginning of the methanol induction and after 20, 45, 119.5, 142.5, 145.5 and 167 hours, respectively.

15 Figure 5: Map of pV4 expression plasmid for the expression of the *Talaromyces emersonii* CBHI / *Trichoderma reesei*-CBD fusion peptide (CBH-ah) in *Trichoderma reesei*. Replicon: pUC19 for replication in *E. coli*. cbh1 5': 5' promoter region of the *Trichoderma* CBHI gene; cbh1 signal peptide: Coding sequence for the *Trichoderma reesei* CBHI leader peptide; CBH-a: *Talaromyces emersonii* CBHI / *Trichoderma reesei*-CBD fusion peptide: coding region for SEQ ID NO: 18; cbh1 Terminator: 3' termination region of the *Trichoderma reesei* CBHI locus; hygromycine resistance: coding region of the hygromycine phosphotransferase under control of a *Trichoderma reesei* phosphoglycerate kinase promoter; cbh1 3': homology sequence to the termination region of the *Trichoderma reesei* CBHI locus for double crossover events.

25 Figure 6: SDS-Page of *Trichoderma reesei* culture supernatants. Lane 1 shows the expression pattern of a replacement strain carrying a *Talaromyces emersonii* CBHI / *Trichoderma reesei*-CBD fusion (CBH-ah) in place of the native CBHI gene. In comparison lane 2 shows the pattern for the unmodified strain under same conditions. M: molecular size marker.

30 Figure 7: Determination of IT50 values from Substrate Conversion Capacity vs. temperature graphs after normalization. For the normalization step the maximum and the minimum fluorescence values for the selected temperature are correlated to 1 or 0, respectively. Linear interpolation to  $F'(T)=0.5$  between the nearest two temperature points with normalized values next to 0.5 results in the defined IT50 temperature.

35 Figure 8: Normalized Conversion Capacity vs. temperature graphs of "wt" *Talaromyces emersonii* CBHI / *Trichoderma reesei*-CBD fusions (CBH-ah: SEQ ID NO: 18 = SEQ ID NO: 2 + 6x His-Tag) and mutants based on 4-Methylumbelliferyl - $\beta$ -D-lactoside hydrolysis results evaluated at various temperatures. The fluorescence values were normalized according to figure 8 over the temperature range from 55°C to 75°C.

40 A...wt;  
B...G4C,A72C;  
C...G4C,A72C,Q349K;  
D...G4C,A72C,D181N,Q349K;  
E...Q1L,G4C,A72C,D181N,E183K,Q349R;  
F...QL,G4C,A72C,S86T,D181N,E183K,D320V,Q349R;  
45 G...G4C, A72C,E183K,D202Y,N310D,Q349R;  
H ... Q1L,G4C,A72C, A145T,H203R,Q349K,T403K;

50 Figure 9: Glucose yields of hydrolysis of pretreated straw with wt and mutated *Talaromyces emersonii* CBHI / *Trichoderma reesei*-CBD (CBH-ah) fusion protein after hydrolysis for 48 hours in the presence of a  $\beta$ -glycosidase. The variants are characterized by the following mutations with respect to SEQ ID NO: 18 and were expressed from *Pichia pastoris* in shake flask cultures and isolated from the supernatant by affinity chromatography using Ni-NTA.

55 A: wt  
B: G4C,A72C  
C: G4C,A72C,Q349K  
D: G4C,A72C, D181N,Q349K  
E: Q1L,G4C,A72C,D181N,E183K,Q349R  
F: Q1L,G4C,A72C,S86T,D181N,E183K,D320V,Q349R

G: G4C, A72C, E183K,D202Y,N310D,Q349R

Figure 10: Alignment of SEQ ID NO: 2 with the *Trichoderma reesei* CBHI. The alignment matrix blosum62mt2 with gap opening penalty of 10 and gap extension penalty of 0.1 was used to create the alignment.

5

### Detailed description of the invention

**[0034]** The present invention discloses a polypeptide having cellobiohydrolase activity, which comprises an amino acid sequence with at least 85 % sequence identity to SEQ ID NO: 2 wherein the amino acid residue at position Q1 of SEQ ID NO: 2 is modified by substitution or deletion. "Cellobiohydrolase" or "CBH" refers to enzymes that cleave cellulose from the end of the glucose chain and produce cellobiose as the main product. Alternative names are 1,4-beta-D-glucan cellobiohydrolases or cellulose 1,4-beta-cellobiosidases. CBHs hydrolyze the 1,4-beta-D-glucosidic linkages from the reducing or non-reducing ends of a polymer containing said linkages. "Cellobiohydrolase I" or "CBH I" act from the reducing end of the cellulose fiber. "Cellobiohydrolase II" or "CBH II" act from the non-reducing end of the cellulose fiber. Cellobiohydrolases typically have a structure consisting of a catalytic domain and one or more "cellulose-binding domains" or "CBD". Such domains can be located either at the N- or C-terminus of the catalytic domain. CBDs have carbohydrate-binding activity and they mediate the binding of the cellulase to crystalline cellulose and presence or absence of binding domains are known to have a major impact on the processivity of an enzyme especially on polymeric substrates.

**[0035]** The parental sequence is given in SEQ ID NO: 2. The sequence derives from the C-terminal fusion of the linker domain and cellulose binding domain of *Trichoderma reesei* CBHI (SEQ ID NO: 4) to the catalytic domain of *Talaromyces emersonii* CBHI (SEQ ID NO: 5).

**[0036]** In a preferred aspect, the invention discloses protein variants that show a high activity at high temperature over an extended period of time. Preferably, the polypeptide of the present invention maintains 50 % of its maximum substrate conversion capacity when the conversion is done for 60 minutes at a temperature of 60 °C or higher. The respective temperature is also referred to as the IT50 value. In other words, the IT50 value is preferably 60 °C or higher. "Substrate Conversion Capacity" of an enzyme is herein defined as the degree of substrate conversion catalyzed by an amount of enzyme within a certain time period under defined conditions (Substrate concentration, pH value and buffer concentration, temperature), as can be determined by end-point assaying of the enzymatic reaction under said conditions. "Maximum Substrate Conversion Capacity" of an enzyme is herein defined as the maximum in Substrate Conversion Capacity found for the enzyme within a number of measurements performed as described before, where only one parameter, e.g. the temperature, was varied within a defined range. According to the present invention, the assay described in Example 8 is used to determine these parameters.

**[0037]** Furthermore, the disclosed polypeptides have preferably an IT50 value in the range of 62 to 70 °C, more preferably 65 to 70 °C.

**[0038]** The polypeptide of the present invention preferably comprises an amino acid sequence having at least 90 %, preferably at least 95 %, more preferably at least 99 % sequence identity to SEQ ID NO: 2, wherein the amino acid residue at position Q1 of SEQ ID NO: 2 is modified by substitution or deletion. Furthermore, it is particularly preferred that the amino acid sequence of the polypeptide has the sequence as defined by SEQ ID NO: 2, wherein the amino acid residue at position Q1 of SEQ ID NO: 2 is modified by substitution or deletion, or a sequence as defined by SEQ ID NO: 2 wherein the amino acid residue at position Q1 of SEQ ID NO: 2 is modified by substitution or deletion wherein 1 to 75, more preferably 1 to 35 amino acid residues are substituted, deleted, or inserted.

**[0039]** Particularly preferred are variants of the protein of SEQ ID NO: 2, wherein the amino acid residue at position Q1 of SEQ ID NO: 2 is modified by substitution or deletion. "Protein variants" are polypeptides whose amino acid sequence differs in one or more positions from this parental protein, whereby differences might be replacements of one amino acid by another, deletions of single or several amino acids, or insertion of additional amino acids or stretches of amino acids into the parental sequence. Per definition variants of the parental polypeptide shall be distinguished from other polypeptides by comparison of sequence identity (alignments) using the ClustalW Algorithm (Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., Valentin F., Wallace I.M., Wilm A., Lopez R., Thompson J.D., Gibson T.J. and Higgins D.G. (2007) ClustalW and ClustalX version 2. *Bioinformatics* 23(21): 2947-2948). Methods for the generation of such protein variants include random or site directed mutagenesis, site-saturation mutagenesis, PCR-based fragment assembly, DNA shuffling, homologous recombination in-vitro or in-vivo, and methods of gene-synthesis.

**[0040]** The nomenclature of amino acids, peptides, nucleotides and nucleic acids is done according to the suggestions of IUPAC. Generally amino acids are named within this document according to the one letter code.

**[0041]** Exchanges of single amino acids are described by naming the single letter code of the original amino acid followed by its position number and the single letter code of the replacing amino acid, i.e. the change of glutamine at position one to a leucine at this position is described as "Q1L". For deletions of single positions from the sequence the

## EP 2 357 227 B1

symbol of the replacing amino acid is substituted by the three letter abbreviation "del" thus the deletion of alanine at position 3 would be referred to as "A3del". Inserted additional amino acids receive the number of the preceding position extended by a small letter in alphabetical order relative to their distance to their point of insertion. Thus, the insertion of two tryptophanes after position 3 is referred to as "3aW, 3bW". Introduction of untranslated codons TAA, TGA and TAG into the nucleic acid sequence is indicated as "\*" in the amino acid sequence, thus the introduction of a terminating codon at position 4 of the amino acid sequence is referred to as "G4\*".

**[0042]** Multiple mutations are separated by a plus sign or a slash or a comma. For example, two mutations in positions 20 and 21 substituting alanine and glutamic acid for glycine and serine, respectively, are indicated as "A20G+E21S" or "A20G/E21S" "A20G,E21S".

**[0043]** When an amino acid residue at a given position is substituted with two or more alternative amino acid residues these residues are separated by a comma or a slash. For example, substitution of alanine at position 30 with either glycine or glutamic acid is indicated as "A20G,E" or "A20G/E", or "A20G, A20E".

**[0044]** When a position suitable for modification is identified herein without any specific modification being suggested, it is to be understood that any amino acid residue may be substituted for the amino acid residue present in the position. Thus, for instance, when a modification of an alanine in position 20 is mentioned but not specified, it is to be understood that the alanine may be deleted or substituted for any other amino acid residue (i.e. any one of R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V).

**[0045]** The terms "similar mutation" or "similar substitution" refer to an amino acid mutation that a person skilled in the art would consider similar to a first mutation. Similar in this context means an amino acid that has similar chemical characteristics. If, for example, a mutation at a specific position leads to a substitution of a non-aliphatic amino acid residue (e.g. Ser) with an aliphatic amino acid residue (e.g. Leu), then a substitution at the same position with a different aliphatic amino acid (e.g. Ile or Val) is referred to as a similar mutation. Further amino acid characteristics include size of the residue, hydrophobicity, polarity, charge, pK-value, and other amino acid characteristics known in the art. Accordingly, a similar mutation may include substitution such as basic for basic, acidic for acidic, polar for polar etc. The sets of amino acids thus derived are likely to be conserved for structural reasons. These sets can be described in the form of a Venn diagram (Livingstone CD, and Barton GJ. (1993) "Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation" *Comput. Appl Biosci.* 9: 745-756; Taylor W. R. (1986) "The classification of amino acid conservation" *J.Theor.Biol.* 119; 205-218). Similar substitutions may be made, for example, according to the following grouping of amino acids: Hydrophobic: F W Y H K M I L V A G; Aromatic: F W Y H; Aliphatic: I L V; Polar: W Y H K R E D C S T N; Charged H K R E D; Positively charged: H K R; Negatively charged: E D.

**[0046]** As convention for numbering of amino acids and designation of protein variants for the description of protein variants the first glutamine (Q) of the amino acid sequence QQAGTA within the parental protein sequence given in SEQ ID NO: 2 is referred to as position number 1 or Q1 or glutamine 1. The numbering of all amino acids will be according to their position in the parental sequence given in SEQ ID NO: 2 relative to this position number 1.

**[0047]** The present invention furthermore discloses variants of the polypeptides of the present invention with changes of their sequence at one or more of the positions : G4, A6, T15, Q28, W40, D64, E65, A72, S86, K92, V130, V152, Y155, K159, D181, E183, N194, D202, P224, T243, Y244, I277, K304, N310, S311, N318, D320, T335, T344, D346, Q349, A358, Y374, A375, T392, T393, D410, Y422, P442, N445, R446, T456, S460, P462, G463, H468 and/or V482 of amino acids 1 to 500 of SEQ ID NO: 2, wherein the amino acid residue at position Q1 of SEQ ID NO : 2 is modified by substitution or deletion.

**[0048]** In a preferred embodiment, the variant of the polypeptides of the present invention comprises one or more specific changes of their sequence at the following positions (preferred exchange) or a similar mutation.

Position	Preferred Exchange	Similar mutation
Q1	L	I, L, V, A, G,
G4	C	C, D, E, R, H, K
A6	G, V	I, L, V, G
T15S	S	Q, N
Q28	R	H, K, R
W40	R	H, K, R
D64	N	Q, N, S, T, E
E65	K, V	H, K, R
A72	C, V	M, I, L, V, G, C

EP 2 357 227 B1

(continued)

	Position	Preferred Exchange	Similar mutation
5	S86	T	H, K, R, E, D, C, T, N
	K92	R	H, R
	V130	I	F, W, Y, H, K, M, I, L, A, G
	V152	A, E	D, E, A, I, L, G, P
10	Y155	C	C, D, E, R, H
	K159	E	D, E
	D181	N	Y, H, K, R, C, S, T, N
15	E183	V, K	I, L, V, A, G, R, K, H
	N194	C, R, Y, D, K, I, L, G, Q, S, V	F, W, C, R, Y, D, K, I, L, G, Q, S, V, H
	D202	Y, N, G	A, R, N, C, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V
	P224	L	I, L, V, A, G
20	T243	I, C, R, Y, A, F, Q, P, D, V, W, L, M	H, K, I, C, R, Y, A, F, Q, P, D, V, W, L, M
	Y244	F, H	F, W, H,
	I277	V	G, A
25	K304	R	H, R
	N310	D	C, D, E, R, H
	S311	G, N	I, L, V, A, G, Q, T, D,
	N318	Y	F, W, Y, H
30	D320	V, E, N	W, Y, H, K, R, E, C, S, T, N
	T335	I	F, W, Y, H, K, M, I, L, V, A, G
	T344	M	F, W, Y, H, K, M, I, L, V, A, G
35	D346	G, A, E	I, L, V, A, G
	Q349	R, K	H, K, R
	A358	E	F, W, Y, H, K, M, I, L, V, G
	Y374	C, P, R, H, S, A	C, P, R, H, S, A, K, E, D, C, F
40	A375	C, D, N, Y, R, G, L, V, E, G, T, M	H, K, C, D, N, Y, R, Q, L, V, E, G, T, M
	T392	C, D, K	H, K, R, E, D, C
	T393	A	I, L, V, A, G,
45	D410	G	F, W, Y, H, K, M, I, L, V, A, G
	Y422	F	H, F, W
	P442	S, del	S, del, T
	N445	D	D, E, Q
50	R446	S, G	A, S, G, V, I, L, C, P
	T456	A	S, A, G, I, L, V, C, P
	S460	L, P	G, A, I, L, P, V
55	P462	L, del	G, A, I, L, V, del
	G463	D	D, E
	H468	L, Q, R	K, R, E, D, C, S, T, N

EP 2 357 227 B1

(continued)

Position	Preferred Exchange	Similar mutation
V482	A, I	G, L, A, I

5

**[0049]** Even more preferably, the variant of the polypeptides of the present invention comprises an amino acid sequence selected from the sequences with mutations with respect to SEQ ID NO: 2, wherein the amino acid residue at position Q1 of SEQ ID NO : 2 is modified by substitution or deletion, optionally fused with a C-terminal 6x-His Tag, listed in the following Table.

10

	Mutations with respect to SEQ ID NO: 2
75	Q1L,G4C,A72C,Q349K
88	Q1L,G4C,A72C,S86T,Q349R
89	Q1L,G4C,A72C,D181N,Q349R
90	Q1L,G4C,A72C,E183K,Q349R
91	Q1L,G4C,A72C,D181N,E183K,Q349R
92	Q1L,G4C,A72C,D320V,Q349R
93	Q1L,G4C,A72C,S86T,D181N,E183K,D320V,Q349R
98	Q1L,G4C,A72C,Q349R
148	Q1L,G4C,A72C,Q349K,T392M
153	Q1L,G4C,A68T,A72C,Q349K,G439D,R453S
154	Q1L,G4C,A72C,D202N,Q349K
155	Q1L,G4C,A68T,A72C,Q349K
156	Q1L,G4C,A72C,K154R,Q349K,T3931
157	Q1L,G4C,A72C,S193P,Q349K,V482I
158	Q1L,G4C,A72C,H203R,Q349K,P442S
159	Q1L,G4C,A72C,Q349K,H468R
160	Q1L,G4C,A72C,D202N,Q349K,G486D
161	Q1L,G4C,E65K,A72C,Q349K
162	Q1L,G4C,A72C,Q349K,Y422F
163	Q1L,G4C,Q28R,A72C,Q349K,H468L
164	Q1L,G4C,A72C,D181N,D247N,Q349K
165	Q1L,G4C,A72C,D181N,Q349K,T451S
166	Q1L,G4C,Q28R,A72C,Q349K
167	Q1L,G4C,A72C,A145T,H203R,Q349K,T403K
168	Q1L,G4C,A72C,I200F,Q349K,L500I
169	Q1L,G4G,D64N,A72C,Q349K
170	Q1L,G4C,A72C,V152A,Q349K
171	Q1L,G4C,T15S,A72C,Y244F,Q349K
172	Q1L,G4C,A6V,A72C,Q349K
173	Q1L,G4C,A72C,S311N,Q349K,G463D
174	Q1L,G4C,A72C,Y155C,Q349K

40

50

55

(continued)

	Mutations with respect to SEQ ID NO: 2
175	Q1L,G4C,A72C,S311N,Q349K
176	Q1L,G4C,A72C,D346V,Q349K
177	Q1L,G4C,A72C,Q349K,T392K
178	Q1L,G4C,A72C,S311G,Q349K
179	Q1L,G4C,A72C,S311G,Q349K,H468R

**[0050]** In a further aspect, the present invention discloses a nucleic acid encoding the polypeptide of the present invention. The nucleic acid is a polynucleotide sequence (DNA or RNA) which is, when set under control of an appropriate promoter and transferred into a suitable biological host or chemical environment, processed to the encoded polypeptide, whereby the process also includes all post-translational and post-transcriptional steps necessary. The coding sequence can be easily adapted by variation of degenerated base-triplets, alteration of signal sequences, or by introduction of introns, without affecting the molecular properties of the encoded protein. The nucleic acid of the present invention has preferably at least 95 %, more preferably at least 97 %, and most preferably 100% identity to SEQ ID NO: 1. The present invention also provides a vector comprising this nucleic acid and a host transformed with said vector.

**[0051]** The present application also discloses methods for the production of polypeptides of the present invention and variants thereof in various host cells, including yeast and fungal hosts. It also discloses the use of the resulting strains for the improvement of protein properties by variation of the sequence. Furthermore, the present application discloses methods for the application of such polypeptides in the hydrolysis of cellulose.

**[0052]** A further aspect of the application discloses vectors and methods for the production of protein variants of SEQ ID NO: 2, wherein the amino acid residue at position Q1 of SEQ ID NO: 2 is modified by substitution or deletion, expressing them in yeast and testing their activity on cellulosic material by measuring the released mono- and/or oligomeric sugar molecules.

**[0053]** The present application further discloses a method of producing a cellobiohydrolase protein, comprising the steps:

- a. obtaining a host cell, which has been transformed with a vector comprising the nucleic acid of the present invention;
- b. cultivation of the host cell under conditions under which the cellobiohydrolase protein is expressed; and
- c. recovery of the cellobiohydrolase protein.

**[0054]** In a preferred embodiment, the host cell is derived from the group consisting of *Saccharomyces*, *Schizosaccharomyces*, *Kluyveromyces*, *Pichia*, *Hansenula*, *Aspergillus*, *Trichoderma*, *Penicillium*, *Candida* and *Yarrowina*. The host cell is preferably capable of producing ethanol, wherein most preferred yeasts include *Saccharomyces cerevisiae*, *Pichia stipitis*, *Pachysolen tannophilus*, or a methylotrophic yeast, preferably derived from the group of host cells comprising *Pichia methanolica*, *Pichia pastoris*, *Pichia angusta*, *Hansenula polymorpha*.

**[0055]** It has surprisingly been found that the polypeptide according to the present invention and variants thereof can be expressed from yeast at high levels. "Yeast" shall herein refer to all lower eukaryotic organisms showing a unicellular vegetative state in their life cycle. This especially includes organisms of the class *Saccharomycetes*, in particular of the genus *Saccharomyces*, *Pachysolen*, *Pichia*, *Candida*, *Yarrowina*, *Debaromyces*, *Kluyveromyces*, *Zygosaccharomyces*.

**[0056]** Thus, one aspect of the application discloses the expression of the claimed polypeptide and variants thereof in yeast. The efficient expression of this fusion protein (SEQ ID NO: 2) and derivative protein variants of SEQ ID NO: 2 from yeast can be achieved by insertion of the nucleic acid molecule of SEQ ID NO: 1 starting from nucleotide position 1 into an expression vector under control of at least one appropriate promoter sequence and fusion of the nucleotide molecule to an appropriate signal peptide, for example to the signal peptide of the mating factor alpha of *Saccharomyces cerevisiae*.

**[0057]** In a preferred embodiment, the polypeptide of the present invention and variants thereof are expressed and secreted at a level of more than 100 mg/l, more preferably of more than 200 mg/l, particularly preferably of more than 500 mg/l, or most preferably of more than 1 g/l into the supernatant after introduction of a nucleic acid encoding a polypeptide having an amino acid sequence with at least 85% sequence identity to the SEQ ID NO: 2 into a yeast. To determine the level of expression in yeast, the cultivation and isolation of the supernatant can be carried out as described in Example 3.

**[0058]** A further aspect of the application discloses methods for the production of a polypeptide according to the present

invention in a filamentous fungus, preferably in a fungus of the genus *Aspergillus* or *Trichoderma*, more preferably in a fungus of the genus *Trichoderma*, most preferably in *Trichoderma reesei*. "Filamentous fungi" or "fungi" shall herein refer to all lower eukaryotic organisms showing hyphal growth during at least one state in their life cycle. This especially includes organisms of the phylum *Ascomycota* and *Basidiomycota*, in particular of the genus *Trichoderma*, *Talaromyces*, *Aspergillus*, *Penicillium*, *Chrysosporium*, *Phanerochaete*, *Thermoascus*, *Agaricus*, *Pleutrus*, *Irpex*. The polypeptide is expressed by fusion of the coding region of a compatible signal sequence to the nucleic acid molecule starting with nucleotide position 52 of SEQ ID NO: 3, as it was done in SEQ ID NO: 3 with the signal sequence of the *Trichoderma reesei* CBHI, and the positioning of the fusion peptide under control of a sufficiently strong promoter followed by transfer of the genetic construct to the host cell. Examples for such promoters and signal sequences as well as techniques for an efficient transfer have been described in the art.

**[0059]** In a further aspect the present application further discloses a method for identifying polypeptides having cellobiohydrolase activity, comprising the steps of:

- a. Generating a library of mutant genes encoding mutant proteins by mutagenesis of a nucleic acid according to claim 9 or a nucleic acid having the sequence defined by SEQ ID NO: 6 (encoding SEQ ID NO: 5), preferably having the sequence defined by SEQ ID NO: 1;
- b. Inserting each mutant gene into an expression vector;
- c. Transforming yeast cells with each expression vector to provide a library of yeast transformants;
- d. Cultivation of each yeast transformant under conditions under which the mutant protein is expressed and secreted;
- e. Incubating the expressed mutant protein with a substrate;
- f. Determining the catalytic activity of the mutant protein;
- g. Selecting a mutant protein according to the determined catalytic activity.

**[0060]** Specifically, step d. may be performed by utilizing a well-plate format. This format preferably allows the high-throughput performance of the method for identifying polypeptides having cellobiohydrolase activity.

**[0061]** Preferably, the steps e. to g. of the method for identifying polypeptides having cellobiohydrolase activity are performed as follows:

- e. Incubating the expressed mutant protein with cellulosic material;
- f. Determining the amount of released sugar;
- g. Selecting a mutant protein according to the amount of released sugar.

**[0062]** In another embodiment, the method for identifying polypeptides having cellobiohydrolase activity comprises the additional steps of:

- h. Sequencing the selected mutant gene or protein;
- i. Identifying the amino acid modification(s) by comparing the sequence of the selected mutant protein with the amino acid sequence of SEQ ID NO: 2.

**[0063]** The present application further discloses a method of preparing a polypeptide having cellobiohydrolase activity, comprising the steps:

- a. Providing a polypeptide having cellobiohydrolase activity comprising an amino sequence having at least 70 % sequence identity to the catalytic domain of SEQ ID NO: 2 (SEQ ID NO: 5);
- b. Identifying the amino acids of this polypeptide which correspond to the amino acids which are modified with respect to the amino acid sequence of SEQ ID NO: 2, as identified in step i. of the method for identifying polypeptides having cellobiohydrolase activity; and
- c. Preparing a mutant polypeptide of the polypeptide provided in step a. by carrying out the amino acid modification(s) identified in step b. through site-directed mutagenesis.

**[0064]** Preferably, the polypeptide provided in step a. of the method of preparing a polypeptide having cellobiohydrolase activity is a wild type cellobiohydrolase derived from *Trichoderma reesei*.

**[0065]** The present application further discloses polypeptides having cellobiohydrolase activity, which are obtainable by the method of preparing a polypeptide having cellobiohydrolase activity according to the present application.

**[0066]** Furthermore, the present invention provides a composition comprising a polypeptide and/or variants thereof of the present invention and one or more cellulases, e.g. one or more endoglucanases and/or one or more beta-glucosidases and/or one or more further cellobiohydrolases and/or one or more xylanases. "Cellulases" or "Cellulolytic enzymes" are defined as enzymes capable of hydrolysing cellulosic substrates or derivatives or mixed feedstocks comprising cellulosic

EP 2 357 227 B1

polymers. Such enzymes are referred to as having "cellulolytic activity", thus being able to hydrolyze cellulose molecules from such material into smaller oligo- or monosaccharides. Cellulolytic enzymes include cellulases and hemicellulases, in particular they include cellobiohydrolases (CBHs), endoglucanases (EGs) and beta-glucosidases (BGLs).

**[0067]** The present application further discloses a polypeptide having cellobiohydrolase activity, wherein the polypeptide comprises an amino acid sequence having at least 80 %, preferably at least 95%, more preferably at least 98%, even more preferably at least 99%, and most preferably 100% sequence identity to SEQ ID NO: 5, wherein one or more of the following amino acid residues of the sequence defined by SEQ ID NO: 5 are modified by substitution or deletion of: Q1, G4, A6, T15, Q28, W40, D64, E65, A72, S86, K92, V130, V152, Y155, K159, D181, E183, N194, D202, P224, T243, Y244, I277, K304, N310, S311, N318, D320, T335, T344, D346, Q349, A358, Y374, A375, T392, T393, D410 and/or Y422 of amino acids 1 to 440 of SEQ ID NO: 5.

**[0068]** In a preferred embodiment, the polypeptide having cellobiohydrolase activity with an amino acid sequence having at least 80 % sequence identity to SEQ ID NO: 5 comprises one or more of the following modified amino acid residues of the sequence defined by SEQ ID NO: 5: Q1L, G4, A6G/V, T15S, Q28Q/R, W40R, D64N, E65K/V, A72V, S86T, K92K/R, V130I/V, V152A/E, Y155C, K159E, D181N, E183V/K, N194C/R/Y/D/K/I/UG/Q/S/V, D202Y/N/G, P224L, T243I/R/Y/A/F/Q/P/D/V/W/L/M, Y244F/H, I277V, K304R, N310D, S311G/N, N318Y, D320V/E/N, T335I, T344M, D346G/A/E/V, Q349R/K, A358E, Y374C/P/R/H/S/A, A375D/N/Y/R/Q/L/V/E/G/T/M, T392C/D/K, T393A, D410G, Y422F.

**[0069]** More preferably, the polypeptide having cellobiohydrolase activity comprises one or more modified amino acid residues of the sequence defined by SEQ ID NO: 5 as indicated in the following Table:

	Mutations with respect to SEQ ID NO: 5
1	G4C,Y163C
2	E183V
3	W40R
4	S311N
5	T335I
6	T48A
7	W40R,M234K
8	E65K
9	T344M
10	A72V
11	I277V
12	D346G
13	S418P
14	G4C,W40R,A72C
15	W40R,T344M
16	W46R,Q349K
17	W40R,T344M,Q349K
18	G4C,A72C,T344M
19	G4C,A72C,Q349K
20	G4C,A72C,T344M,Q349K
21	G4C,W40R,A72C,T344M
22	G4C,W40R,A72C,Q349K
23	G4C,W40R,A72C,T344M,Q349K
24	N54S,N194Y
25	V130I,H350Y
26	K92R

**EP 2 357 227 B1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Mutations with respect to SEQ ID NO: 5	
27	T325I
28	Y60H
29	T229A
30	D320E
31	E65V,Q349R
32	T392M
33	G4C,A72C,D346G
34	G4C,A72C,Q349R
35	G4C,A72C,D346G,Q349R
36	G4C,A72C,T344M,D346G,Q349R
37	G4C,A6G,A72C,Q349K
38	G4C,A72C,Q349K,A376T
39	G4C,A72C,Q349K,E65V,Q349R
40	G4C,A72C,Q349K,S24N
41	G4C,P12Q,A72C,Q349K,Q362H
42	N194C,Y374C
43	T243C,A375C,N194C,Y374C
44	G4C,A72C,Q349K,D320V
45	G4C,A72C,Q349K,S86T
46	G4C,A72C,D181N,Q349K
47	G4C,A72C,E183V,K304R,Q349K
48	Q1L,G4C,A72C,Q349K
49	G4C,A72C,S86T,M234V,Q349K
50	G4C,A72C,E183K,Q349K
51	G4C,A72C,S311G,Q349K
52	G4C,D64N,A72C,Q349K
53	G4C,A72C,D181 N,P224L,Q349K
54	G4C,A72C,E183K,N318Y,Q349K
55	G4C,A72C,E183V,Q349K
56	G4C,A72C,N194C,Y374C
57	G4C,A72C,N194C,Q349R,Y374C
58	N194R,Y374D
59	T243R,A375D
60	N194R,T243R,Y374D,A375D
61	Q1L,G4C,A72C,S86T,Q349R
62	Q1L,G4C,A72C,D181N,Q349R
63	Q1L,G4C,A72C,E183K,Q349R
64	Q1L,G4C,A72C,D181N,E183K,Q349R

**EP 2 357 227 B1**

(continued)

	Mutations with respect to SEQ ID NO: 5
5	65 Q1L,G4C,A72C,D320V,Q349R
	66 Q1L,G4C,A72C,S86T,D181N,E183K,D320V,Q349R
	67 G4C,A72C,Q349R,V367A
	68 G4C,A72C,E183K,D202Y,N310D,Q349R
10	69 Q1L,G4C,A72C,Q349R
	70 G4C,A72C,G251R,Q349R
	71 G4C,A72C,P224L,F306Y,Q349R
	72 G4C,V32G,N49S,A72C,S193L,Q349R
15	73 G4C,A72C,D181N,Q349R
	74 G4C,A72C,D202N,Q349R
	75 A72V,T335I,D346A,T393A,P436S
20	76 A72V,T335I,D346A,T393A
	77 W40R,D346A,T393A
	78 A72V,D346A,T393A
25	79 G4C,E65V,A72C,Q349R
	80 G4C,A72C,D202G,D320N,Q349R,A358E
	81 G4C,A72C,D320V,Q349R
	82 G4C,E65V,A72C,Y244H,Q349R
30	83 G4C,A72C,E183K,Q349R
	84 G4C,A72C,E183K,D346E,Q349R
	85 G4C,A72C,S311G,Q349R
35	86 G4C,A72C,P224L,Q349R
	87 G4C,A72C,S236Y,Q349R
	88 A72V,D320V,D346A
	89 A72V,D346A
40	90 W40R,T335I,D346A,T393A
	91 G4C,A72C,D320V,Q349K
	92 G4C,A72C,S311G,D320V,Q349K
45	93 Q1L,G4C,A72C,Q349K,T392M
	94 D320V,Q349K
	95 G4C,E172C,D202V,D320V,Q349K
	96 G4C,A72C,D320V,D346V,Q349K
50	97 Q1L,G4C,A72C,D202N,Q349K
	98 Q1L,G4C,A68T,A72C,Q349K
	99 Q1L,G4C,A72C,K154R,Q349K,T393I
55	100 Q1L,G4C,E65K,A72C,Q349K
	101 Q1L,G4C,A72C,D181N,D247N,Q349K
	102 Q1L,G4C,Q28R,A72C,Q349K

EP 2 357 227 B1

(continued)

	Mutations with respect to SEQ ID NO: 5
5	103 Q1L,G4C,A72C,A145T,H203R,Q349K,T403K -
	104 Q1L,G4C,D64N,A72C,Q349K
	105 Q1L,G4C,A72C,V152A,Q349K
	106 Q1L,G4C,T15S,A72C,Y244F,Q349K
10	107 Q1L,G4C,A6V,A72C,Q349K
	108 Q1L,G4C,A72C,Y155C,Q349K
	109 C11L,G4C,A72C,S311N,Q349K
	110 Q1L,G4C,A72C,D346V,Q349K
15	111 Q1L,G4C,A72C,Q349K,T392K
	112 Q1L,G4C,A72C,S311G,Q349K
	113 G4C,A72C,N194K,T243Y,Q349R,A375N
20	114 G4C,A72C,N194D,T243A,Q349R,Y374P,A375Y
	115 G4C,A72C,N194I,T243Y,Q349R,Y374P,A375R
	116 G4C,A72C,N194K,Q349R,Y374P,A375Q
25	117 G4C,A72C,N194L,T243Y,Q349R,Y374R,A375L
	118 G4C,A72C,N194G,T243F,Q349R,Y374P,A375R
	119 G4C,A72C,N194L,T243Q,Q349R,Y374P,A375V
	120 G4C,A72C,N194K,T243P,Q349R,Y374H,A375E
30	121 G4C,A72C,N194I,T243D,Q349R,Y374P,A375Y
	122 G4C,A72C,N194Q,T243V,Q349R,Y374P,A375Y
	123 G4C,A72C,N194S,T243W,Q349R,Y374S,A375G
35	124 G4C,A72C,N194Y,T243L,Q349R,Y374S,A375R
	125 G4C,A72C,N194V,T243M,Q349R,Y374A,A375T
	126 G4C,A72C,T243G,Q349R,Y374P,A375M
	127 G4C,A72C,T243Q,Q349R,Y374P,A375M
40	128 G4C,A72C,N194Y,T243V,Q349R,Y374P

**[0070]** Furthermore, the present application discloses a polypeptide having cellobiohydrolase activity comprising an amino acid sequence having at least 85%, preferably at least 95%, more preferably at least 98%, even more preferably at least 99%, and most preferably 100% sequence identity to SEQ ID NO:12 wherein one or more of the following amino acid residues of the sequence defined by SEQ ID NO: 12 are modified by substitution or deletion: Q1, T15, Q28, W40, C72, V133, V155, Y158, T162, Y247, N307, G308, E317, S341, D345, Y370, T389, Q406, N441, R442, T452, S456, P458, G459, H464 and/or V478.

**[0071]** In a preferred embodiment, the polypeptide having cellobiohydrolase activity comprising an amino acid sequence having at least 85 % sequence identity to SEQ ID NO: 12 comprises one or more of the following modified amino acid residues of the sequence defined by SEQ ID NO: 12:

	Exchange with respect to SEQ ID NO: 12
55	1 Q1L
	2 T15S
	3 Q28R

EP 2 357 227 B1

(continued)

5  
10  
15  
20  
25  
30  
35

	Exchange with respect to SEQ ID NO: 12
4	W40R
5	C72V
6	V133I
7	V155A,E
8	Y158C
9	T162E
10	Y247F,H
11	N307D
12	G308N
13	E317V,N
14	S341M
15	D345R,K
16	Y370P,R,H,S,A
17	T389A
18	Q406G
19	N441D
20	R442S,G
21	T452A
22	S456L,P
23	P458L,del
24	G459D
25	H464L,Q,R
26	V478A,I

40  
45  
50  
55

**[0072]** Another aspect of the disclosure relates to the application of the isolated polypeptides and variants thereof of the present invention for the complete or partial hydrolysis of cellulosic material. The cellulosic material can be of natural, processed or artificial nature. "Cellulosic material" herein shall be defined as all sorts of pure, non-pure, mixed, blended or otherwise composed material containing at least a fraction of  $\beta$ -1-4-linked D-glucosyl polymers of at least 7 consecutive subunits. Prominent examples of cellulosic materials are all sort of cellulose containing plant materials like wood (soft and hard), straw, grains, elephant grass, hay, leaves, cotton and materials processed there from or waste streams derived from such processes. Cellulosic material used in an enzymatic reaction is herein also referred to as cellulosic substrate.

**[0073]** The hydrolysis of the cellulose material can be a sequential process following cellobiohydrolase production or contemporary to the production in the yeast cell (consolidated bioprocess). The expression of cellulolytic enzymes in yeast is of special interest due to the ability of many yeasts to ferment the released sugars (C6 or C5) to ethanol or other metabolites of interest.

**[0074]** A further aspect of the application thus relates to the application of whole cells expressing the polypeptide or variant thereof according to the present invention for the processing of cellulosic materials.

**[0075]** In a particular aspect, the present application discloses the use of a polypeptide and variants thereof or the composition of the present invention for the enzymatic degradation of cellulosic material, preferably lignocellulosic biomass, and/or for textiles processing and/or as ingredient in detergents and/or as ingredient in food or feed compositions.

## Examples

Example 1: Preparation of Pichia pastoris expression plasmid

5 **[0076]** Expression plasmids for the constitutive expression of protein from transformed *Pichia pastoris* hosts are prepared by assembly of an expression cassette consisting of a *Pichia pastoris* glyceraldehyde phosphate dehydrogenase (GAP) promoter, a *Saccharomyces cerevisiae* SP $\alpha$  (mating factor alpha signal peptide), a multiple cloning site (MCS) and the 3'-GAP-terminator sequence. For selection purposes a kanamycine resistance gene is used under control of the EM7 or TEF promoter for bacterial or yeast selection purposes, respectively. The resulting plasmid vectors are  
10 designated as pV1 (Figure 1) and pV2 (alternative MCS) Transformation and expression cultivation are done essentially as described by Waterham, H. R., Digan, M. E., Koutz, P. J., Lair, S. V., Cregg, J. M. (1997). Isolation of the *Pichia pastoris* glyceraldehyde-3-phosphate dehydrogenase gene and regulation and use of its promoter. *Gene*, 186, 37-44 and Cregg, J.M.: *Pichia* Protocols in *Methods in Molecular Biology*, Second Edition, Humana Press, Totowa New Jersey 2007.

15

Comparative example 1: Construction of *Pichia pastoris* expression constructs for CBHI sequences

**[0077]** CBHI genes of *Trichoderma viride* (CBH-f), *Humicola grisea* (CBH-d), *Thermoascus aurantiacus* (CBH-e), *Talaromyces emersonii* (CBH-b), and fusions of the cellulose binding domain of *Trichoderma reesei* CBHI with the *Talaromyces emersonii* CBHI (CBH-a) or the *Humicola grisea* CBHI (CBH-g) are amplified using the oligo nucleotide pairs and templates (obtained by gene synthesis) as given in the table. The fusion gene encoding SEQ ID NO: 2 is generated by overlap extension PCR using the PCR-Fragments generated from SEQ ID NOs:5 and 11. Phusion DNA polymerase (Finnzymes) is used for the amplification PCR.

25

Table 1: Primers and templates for the amplification of CBH-a, CBH-b, CBH-d, CBH-e, CBH-f and CBH-g

30

35

40

45

50

55

	Fragment	Primer forward	Primer reverse	Template
CBH-f	<i>Trichoderma viride</i> CBHI	<b>GAGGCGGAAGCACCC</b> TCTcaatctgcttgaccttgc gtc	<b>GGAGACGCAGAGCC</b> Cttattacaggcactgcgagt agt	SEQID NO. 13
CBH-d	<i>Humicola grisea</i> CBHI	<b>GAGGCGGAAGCACCC</b> TCTcagcaggctggtactatta ctgc	<b>GGAGACGCAGAGCC</b> Cttacacgttcacggtagaac cgattgggc	SEQID NO. 7
CBH-e	<i>Thermoascus aurantiacus</i> CBHI	<b>GAGGCGGAAGCACCC</b> TCTcagcaggccggtaccgta accgc	<b>GGAGACGCAGAGCC</b> CTTAtttagttggcggtgaag gtcgagt	SEQID NO. 9
CBH-b	<i>Talaromyces emersonii</i> CBHI	<b>GAGGCGGAAGCACCC</b> TCTcagcaggccggcagcggc gacggc	<b>GGAGACGCAGAGCC</b> CTTAtcacgaagcggtgaa ggtcgagt	SEQID NO. 5
CBH-a part1	<i>Talaromyces emersonii</i> CBH fusion fragment part1	<b>GAGGCGGAAGCACCC</b> TCTcagcaggccggcagcggc gacggc	<b>ATTACCTGTGCTACC</b> gatcggaccaacttaatgttc g	SEQID NO. 5
CBH-a part2	<i>Trichoderma reesei</i> CBHI binding domain fusion fragment part2	<b>AAGTTTGGTCCGATCg</b> gtagcacaggtaatccttcagg	<b>GGAGACGCAGAGCC</b> CTTATTAtagacactgtga gtagtaagggt	SEQID NO.11

EP 2 357 227 B1

(continued)

	Fragment	Primer forward	Primer reverse	Template
5	CBH-a Talaromyces emersonii CBHI fusion protein	<b>GAGGCGGAAGCACCC</b> <b>TCTcagcagggccggcagggc</b> <b>gacggc</b>	<b>GGAGACGCAGAGCC</b> <b>CTTAtcattaatgggtgggt</b> <b>gatgatgag</b>	5a+5b SEQID NO. 2
10	CBH-g part1 Humicola grisea CBHI fusion fragment part1	<b>aggcggaagcatgctgcgagc</b> <b>aggctggtacaattactgc</b>	<b>ggattacctgtaagcttccaat</b> <b>tggtccgaatctgatgtt</b>	SEQID NO. 19
15	CBH-g part2 Trichoderma reesei CBHI binding domain fusion fragment part2	<b>accaattggaagcftaacaggta</b> <b>atccttcaggtggtaatcc</b>	<b>atcttcaggtcgacttatcatt</b> <b>aatgatgatgatgatgggtgtc</b> <b>a</b>	SEQID NO. 11
20	CBH-g Humicola grisea fusion protein	<b>aggcggaagcatgctgcgagc</b> <b>aggctggtacaattactgc</b>	<b>atcttcaggtcgacttatcatt</b> <b>aatgatgatgatgatgggtgtc</b> <b>a</b>	6a+6b SEQID NO. 15

**[0078]** PCR fragments of expected length are purified from agarose gels after electrophoresis using the Promega® SV PCR and Gel Purification kit. Concentration of DNA fragments are measured on a Spectrophotometer and 0,2pmol of fragments are treated with 9U of T4-DNA polymerase in the presence of 2,5mM dATP for 37,5 min at 22,5°C and treated fragments are annealed with T4-DNA-Polymerase/dTTP treated *Sma*I-linearized pV1 plasmid DNA and afterwards transformed into chemically competent Escherichia coli Top10 cells. Deviant from the described procedure the product generated by the primer pair according to the table lane 11 encoding the *Humicola grisea* fusion protein fragments are cloned via the introduced *Sph*I and *Sa*II site to pV2. Transformants are controlled by sequencing of isolated plasmid DNA.

Comparative example 2: Expression of CBHI Genes in Pichia pastoris

**[0079]** Plasmids of Example 2 are transformed to electro-competent *Pichia pastoris* CBS 7435 cells and transformants are used to inoculate cultures in YPD medium containing 200mg/l, which are incubated for 5 days at 27°C in a rotary shaker at 250 rpm. Culture supernatants were separated by centrifugation at 5000xg for 30 minutes in a Sorvall Avant centrifuge. Supernatants were concentrated on spin columns with cut-off size of 10kDa. Protein pattern of such concentrated supernatants were analyzed by SDS-PAGE (Laemmli et al.) and gels were stained with colloidal Commassie blue stain. Enzymatic activity was determined by incubation of the supernatant with 2mM solutions of p-nitrophenyl-β-D-lactoside or 200μM solutions of 4-methyl-umbelliferyl-β-D-lactoside in 50 mM sodium acetate buffer (pH 5) for 1 hour. The reaction was stopped by addition of equal volumes of 1 M sodium carbonate solution and determination of released p-nitrophenol or 4-methyl umbelliferone by measurement of the absorbance at 405 nm or the fluorescence at 360 nm/450 nm excitation/emission.

Comparative example 3: Genome integration and expression of the *Talaromyces emersonii* CBHI-*T. reesei* CBHII-CBD fusion sequence in *Pichia pastoris*

**[0080]** The DNA-fragment of the fusion gene are generated by 2 step overlap extension PCR using the oligo nucleotide pairs and synthetic templates as indicated in the table (of Example 2). T4-DNA polymerase treated full length fragment was annealed with the linear pV3 vector fragment by slowly reducing the temperature from 75°C to 4°C. The pV3 plasmid contains a fusion of the mating factor alpha signal peptide to a multiple cloning site, situated downstream the of a *Pichia pastoris* AOX1 promoter. Transformation of the annealed solution into chemical competent E. coli cells yields transformants, which are selected by their Teocine resistance checked for containing expected construct plasmid by restriction analysis and sequencing. pV3-CBH-a plasmid preparations are linearized with *Sac*I and approximately 1 μg of linear DNA-fragments are transformed to *Pichia pastoris* electrocompetent cells. 94 Transformants from YPD-Zeocin plates are afterwards checked for expression by cultivation in 500μl 96-deepwell Plate cultures in BMMY-medium containing 1% methanol and 0.5 % methanol was fed every 24h for 5 days (350 rpm/27°C; humidified orbital shaker with 2,5 cm

## EP 2 357 227 B1

amplitude. Supernatants are tested for activity on 4-MUL and clones with highest expression levels are selected and again evaluated under same conditions.

**[0081]** For fermentation in an Infors Multifors bioreactor the strain producing the highest enzyme concentration is selected. A YPD-Zeocin (100g/l) pre-culture is chosen for inoculation of Mineral medium consisting of phosphate-buffer, magnesium sulphate and chloride, trace elements/biotin and glycerol, with pH calibration using ammonia and phosphoric acid. After metabolism of the batch glycerol (2%) additional glycerol feed is maintained for 1 day before the feed is changed to methanol to shift to inductive conditions for the AOX1 promoter. Under these conditions the fermentation is kept for 5 days. Cells are separated from the fermentation liquid by centrifugation at 5000xg for 30 minutes. Supernatants are analyzed for total Protein using Bradford Reagent and BSA Standards (Biorad). SDS-PAGE / Coomassie Brilliant blue staining is used to analyze the Protein Pattern on the SDS-PAGE.

Example 2: *Trichoderma reesei* expression vector construct

**[0082]** SbfI/SwaI digested pSCMB100 plasmid DNA was transformed into *Trichoderma reesei* SCF41 essentially as described by Penttilä et al 1997. 10 $\mu$ g of linear DNA was used for the transformation of 10<sup>7</sup> protoplasts. Selection of transformants was done by growth of the protoplasts on Mandel's Andreotti media plates with overlay agar, containing hygromycin as selective agent (100mg/l). Transformants were further purified by passage over sporulation media plates and re-selection of spores on hygromycin media. From re-grown mycelia genomic DNA was isolated and the replacement event verified by PCR. Transformants verified in being true replacement strains were further tested for secretion of recombinant protein.

Example 3: Expression of *Talaromyces emersonii* CBHI / *Trichoderma reesei* -CBD fusion (CBH-ah) from *Trichoderma reesei*

**[0083]** Expression of recombinant CBHI replacement strains of *Talaromyces emersonii* CBHI / *Trichoderma reesei* -CBD fusion with 6x His-Tag in *Trichoderma reesei* Q6A (ATCC 13631) was done in shakeflask cultures containing 40ml Mineral medium containing 2% Avicel in 300ml flasks and cultivation at 30°C/250rpm for 6 days. Supernatants recovered by centrifugation and further analyzed by SDS-PAGE and Bradford Protein assays.

Example 4: Screening thermo stability variants

**[0084]** Random mutagenesis libraries of the *Talaromyces emersonii* CBHI / *Trichoderma reesei* -CBD fusion (with 6x His-Tag) gene were generated using error prone PCR applying manganese containing bufferers and imbalanced dNTP concentrations in the *Taq*-DNA polymerase reaction mixture, used for PCR-amplification, essentially as described by Craig and Joyce (R.Craig Cadwell and G.F. Joyce, 1995. Mutagenic PCR, in PCR Primer: a laboratory manual, ed. C. W. Dieffenbach and G. S. Dveksler, Cold Spring Harbor Press, Cold Spring Harbor, ME, 583-589). As template the wild type fusion gene (SEQ ID NO: 17) or mutants thereof were chosen. Mutated PCR-Fragments were cloned to the pPKGME Plasmid using SphI and *Hind*III endonucleases and T4-DNA-ligase.

**[0085]** Libraries of the *Talaromyces emersonii* CBHI / *Trichoderma reesei* -CBD fusion (with 6x His-Tag) gene variants were distributed in 1536 well plates with well occupation number close to 1. Enzyme was expressed over 7 days in a volume of 4 $\mu$ l YPG-G418 medium. For evaluation of the properties of the variants 2 $\mu$ l samples of culture supernatants were transferred to plates containing a suspension of milled straw, acetate buffer and beta-glucosidase. After incubation of the sealed reaction plates for 48 hours at defined temperatures the glucose concentration was determined using Amplex red in the presence of GOX and HRP by analyzing the fluorescence level. Best-performing Hits were re-cultivated and re-evaluated. Plasmids of confirmed CBH-ah variants were recovered (Pierce DNAzol Yeast genomic DNA Kit) and sequenced using oligonucleotides alpha-f (5' TACTATTGCCAGCATTGCTGC-3') and oli740 (5'-TCAGCTATTTACAT-ACAAATCG-3').

Example 5: Determination of Substrate Conversion Capacity at different temperatures for indication of the thermostability of CBH-ah-Variants using 4-methylumbellifery- $\beta$ -D-lactoside (4-MUL)

**[0086]** For precise comparison of the thermal stability culture supernatants containing the secreted cellobiohydrolase variants were diluted tenfold in sodium acetate buffer (50mM, pH 5) and 10 $\mu$ l samples were incubated with 90 $\mu$ l of 200 $\mu$ M 4-MUL (in buffer) in the temperature gradient of an Eppendorff Gradient Thermocycler. A temperature gradient of 20°C reaching from 55°C to 75°C was applied to 12 reaction mixtures for for each sample for one hour. The temperature profile could be recorded after addition of 100 $\mu$ l 1 M sodium carbonate solution to each reaction and measurement of the fluorescence intensity at 360nm/454nm in a Tecan Infinite M200 plate reader. For comparison of the thermostability the values were normalized between 1 and 0 for the maximum and minimum fluorescence count (Figure 7).

EP 2 357 227 B1

Table 2: Listing of Mutants of SEQ ID NO: 18 with improved IT50 values.

	Mutations with respect to SEQ ID NO: 18	IT50 [°C]
5	none	59,8
	1 N194R,Y374D	59,8
	2 S467T	60,1
10	3 G4C,A72C,Q349K,S24N	60,1
	4 T392M	60,2
	5 W40R,D320V,T393A,N445D	60,2
	6 W40R	60,3
15	7 R446G	60,6
	8 D346G,R453G	60,9
	9 Y496F	60,9
20	10 T3351,D346A,T393A,D410G	61,0
	11 T2431,T325A,V482A	61,0
	12 N194R,T243R,Y374D,A375D	61,1
	13 E65K	61,1
25	14 T48A	61,2
	15 G4C,A72C,T344M	61,2
	16 T243R,A375D	61,3
30	17 W40R,K159E,N445D,A501S	61,3
	18 T344M	61,3
	19 W40R,M234K	61,3
	20 Q349R,T393A,P436S,N445D	61,4
35	21 Q349R,A354T,D373E,N445D	61,4
	22 G4C,W40R,A72C,T344M	61,4
	23 G4C,A72C,N194L,T243Y,Q349R,Y374R,A375L	61,5
40	24 G4C,D64N,A72C,Q349K	61,5
	25 W40R,T344M	61,5
	26 W40R,D346A,T393A	61,6
	27 N158D,G486S,Y495C	61,6
45	28 D320E	61,6
	29 A72V	61,6
	30 E183V	61,6
50	31 Q349R,N445D	61,6
	32 W40R,C489R	61,7
	33 W40R,Q349K	61,9
	34 G4C,A72C,Q349K,E65V,Q349R	61,9
55	35 S311N	62,0
	36 D320V,D346A,Q349R,T393A,N445D	62,1

EP 2 357 227 B1

(continued)

	Mutations with respect to SEQ ID NO: 18	IT50 [°C]
5	37 T335I	62,2
	38 A72V,D346A	62,2
	39 D320V,D346A,T393A,N445D	62,2
	40 G4C,A72C,N194S,T243W,Q349R,Y374S,A375G	62,3
10	41 E65V,Q349R	62,3
	42 A72V,T335I,D346A,N445D	62,3
	43 G4C,A72C,N194L,T243,Q,Q349R,Y374P,A375V	62,3
15	44 G4C,A72C,D346G	62,3
	45 W40R,T344M,Q349K	62,3
	46 G4C,Y163C	62,4
	47 G4C,V32G,N49S,A72C,S193L,Q349R	62,4
20	48 G4C,A72C,D346G,Q349R	62,6
	49 W40R,D320V,Q349K,P436S,N445D	62,7
	50 G4G,A72C,D181N,Q349R	62,7
25	51 G4C,A72C,Q349K	62,7
	52 A72V,Q349R,N445D	62,8
	53 G4C,A72C,T344M,Q349K	62,8
	54 G4C,A72C,D320V,Q349K	62,8
30	55 G4C,A72C,P224L,F306Y,Q349R	62,9
	56 A72V,T335I,D346A,T393A,N445D	62,9
	57 G4C,A72C,T344M,D346G,Q349R	63,0
35	58 A72V,D346A,T393A	63,0
	59 G4C,A72C,Q349R,R446S,T456A	63,0
	60 G4C,W40R,A72C,T344M,Q349K	63,0
40	61 A72V,D320V,D346A	63,1
	62 G4C,A72C,N194Y,T243L,Q349R,Y374S,A375R	63,1
	63 G4C,A72C,Q349K,T448A,T449A	63,2
	64 G4C,E65V,A72C,Y244H,Q349R	63,3
45	65 G4C,A72C	63,3
	66 G4C,A72C,P224L,Q349R,S409L,P429S	63,4
	67 G4C,A72C,D202G,D320N,Q349R,A358E	63,4
50	68 G4C,A72C,D320V,Q349R,H508R	63,4
	69 G4C,A72C,Q349K,S86T	63,4
	70 A72V,T335I,D346A,T393A,P436S	63,4
	71 G4C,A72C,E183V,K304R,Q349K	63,5
55	72 G4C,A72C,T243G,G3349R,Y374P,A375M	63,5
	73 G4C,A72C,Q349R,T465I	63,6
	74 G4C,A72C,N194V,T243M,Q349R,Y374A,A375T	63,6

EP 2 357 227 B1

(continued)

	Mutations with respect to SEQ ID NO: 18	IT50 [°C]
5	75 G4C,D64N,A72C.Q349R,A358E,P464Q	63,6
	76 G4C,A72C,Q349K,Q28R,S193T,Q490L	63,6
	77 G4C,A72C,E183K,Q349K	63,6
	78 G4C,A72C,S311N,Q349K,A455T,H509Q	63,6
10	79 G4C,A72C,N194K,Q349R,Y374P,A375Q	63,6
	80 G4C,A72C,D181N,Q349K	63,6
	81 W40R,D320V,Q349K,T393A,N445D	63,7
15	82 W40R,T3351,D346A,T393A	63,7
	83 G4C,A72C,N194K,T243P,Q349R,Y374H,A375E	63,7
	84 G4C,A72V,Q349R,P462del	63,8
	85 G4C,A72C,S236Y,Q349R	63,8
20	86 G4C,A72C,S311G,Q349K	63,8
	87 A72V,D320V,T335I,D346A,T393A,N445D	63,8
	88 G4C,A72C,S86T,M234V,Q349K	63,8
25	89 G4C,A72C,G251R,Q349R	63,9
	90 Q1L,G4C,A68T,A72C,Q349K,H505N	63,9
	91 A72V,T335I,D346A,T393A	63,9
	92 G4C,A72C,E183K,Q349R	63,9
30	93 G4C,A72C,Q349R	63,9
	94 Q1L,G4C,A72C,H203R,Q349K,P442S	63,9
	95 G4C,A72C,Q349K,G434S,G470D	64,0
35	96 G4C,W40R,A72C,Q349K	64,0
	97 G4C,A72C,Q349R,V367A	64,0
	98 G4C,A72C,S311G,D320V,Q349K	64,0
	99 W40R,T335I,D346A,T393A,P436S	64,0
40	100 A72V,D346A,T393A,N445D	64,1
	101 Q1L,G4C,A72C,D202N,Q349K	64,1
	102 G4C,A72C,D320V,Q349R	64,1
45	103 Q1L,G4C,A72C,K154R,G1349K,T393I	64,1
	104 G4C,A72C,N194G,T243F,Q349R,Y374P,A375R	64,1
	105 A72V,D320V,D346A,T393A,N445D	64,1
	106 G4C,A72C,E183V,Q349K	64,1
50	107 G4C,A72C,E183K,N318Y,Q349K	64,1
	108 G4C,A72C,K92R,Q349K,N493D	64,1
	109 Q1L,G4C,A72C,Q349K	64,2
55	110 M234I,G438del	64,2
	111 G4C,A72C,Q349R,G459D	64,2
	112 G4C,A72C,Q349R,Y422F	64,2

EP 2 357 227 B1

(continued)

	Mutations with respect to SEQ ID NO: 18	IT50 [°C]
5	113 G4C,T48A,A72C,Q349R,P480S	64,2
	114 E187K,D320V,P442del	64,2
	115 G4C,S24N,E65K,A72C,Q349R,I430L,G439D	64,2
	116 A72V,D320V,T335I,D346A,T393A,P436S	64,3
10	117 Q1L,G4C,A72C,S193P,Q349K,V482I	64,3
	118 G4C,A72C,D320V,Q349K,G443D,L492Q	64,3
	119 G4C,A72C,Q349K,D320V	64,4
15	120 G4C,A72C,N194K,T243Y,Q349R,A375N	64,4
	121 Q1L,G4C,Q28R,A72C,Q349K,H468L	64,5
	122 G4C,E65V,A72C,Q349R	64,5
	123 D320V,Q349K	64,5
20	124 G4C,A72C,D181N,P224L,Q349K	64,5
	125 G4C,A72C,T243Q,Q349R,Y374P,A375M	64,5
	126 Q1L,G4C,A72C,D320V,Q349R	64,5
25	127 Q1L,G4C,T15S,A72C,Y244F,Q349K	64,5
	128 G4C,A72C,E183K,D346E,Q349R	64,6
	129 Q1L,G4C,A72C,Q349K,T392M	64,6
	130 G4C,A72C,D202N,S311N,Q349R,N493D	64,6
30	131 G4C,A72C,N194D,T243A,Q349R,Y374P,A375Y	64,6
	132 G4C,A72C,N194Y,T243V,Q349R,Y374P	64,7
	133 Q1L,G4C,A72C,Q349R	64,7
35	134 G4C,A72C,D202N,Q349R,H507Y	64,7
	135 G4C,A72C,P224L,Q349R,A503V	64,7
	136 N194C,Y374C	64,7
	137 Q1L,G4C,A72C,D181N,Q349R	64,8
40	138 G4C,A72C,D320V,D346V,Q349K	64,8
	139 Q1L,G4C,A72C,V152A,Q349K	64,8
	140 G4C,A72C,E183K,D202Y,N310D,Q349R	64,8
45	141 Q1L,G4C,Q28R,A72C,Q349K	64,8
	142 Q1L,G4C,A72C,Q349K,Y422F	64,8
	143 G4C,A72C,D202V,D320V,Q349K,H504Y	64,8
	144 Q1L,G4C,A72C,D181N,D247N,Q349K,S502T	64,8
50	145 Q1L,G4C,A68T,A72C,Q349K,G439D,R453S	64,9
	146 Q1L,G4C,A72C,Q349K,H468R	64,9
	147 Q1L,G4C,D64N,A72C,G1349K	64,9
55	148 G4C,A72C,E183K,Q349R,P464L	64,9
	149 G4C,A72C,N194I,T243Y,Q349R,Y374P,A375R	65,0
	150 Q1L,G4C,A72C,Q349K,H508L	65,0

EP 2 357 227 B1

(continued)

	Mutations with respect to SEQ ID NO: 18	IT50 [°C]
5	151 Q1L,G4C,A72C,E183K,Q349R	65,0
	152 G4C,A72C,S311G,Q349R	65,0
	153 Q1L,G4C,A72C,S311N,Q349K,G463D	65,1
	154 Q1L,G4C,A72C,S86T,Q349R	65,1
10	155 Q1L,G4C,E65K,A72C,Q349K	65,2
	156 Q1L,G4C,A72C,D181N,Q349K,T451S	65,2
	157 Q1L,G4C,A6V,A72C,Q349K	65,3
15	158 G4C,A72C,N194I,T243D,Q349R,Y374P,A375Y	65,3
	159 G4C,A72C,N194C,Y374C	65,6
	160 Q1L,G4C,A72C,A145T,H203R,Q349K,T403K	65,8
	161 Q1L,G4C,A72C,S311G,Q349K	66,0
20	162 Q1L,G4C,A72C,D202N,Q349K,G486D	66,0
	163 Q1L,G4C,A72C,I200F,Q349K,L500I	66,0
	164 Q1L,G4C,A68T,A72C,Q349K	66,1
25	165 Q1L,G4C,A72C,D346V,Q349K	66,2
	166 G4C,A72C,N194Q,T243V,Q349R,Y374P,A375Y	66,3
	167 Q1L,G4C,A72C,Q349K,T392K	66,3
	168 Q1L,G4C,A72C,D181N,E183K,Q349R	66,4
30	169 Q1L,G4C,A72C,S311N,Q349K	66,5
	170 G4C,A72C,N194C,Q349R,Y374C	66,5
	171 Q1L,G4C,A72C,Y155C,Q349K,A503T	67,0
35	172 Q1L,G4C,A72C,S86T,D181N,E183K,D320V,Q349R	67,0

Example 6: Characterization of Variants of the *Talaromyces emersonii* CBH1/*Trichoderma reesei*-CBD fusion (with 6x His-Tag)

40 **[0087]** 80 mL of fermentation broth were concentrated to a final volume of approx. 1mL. After determination of protein concentration (Bradford reagent, Biorad, Germany, Standard is BSA form Sigma-Aldrich, Germany) 1.2mg of protein were purified with the Ni-NTA Spin kit (Qiagen, Germany). The purified CBH1 fraction was subsequently assayed by performing a hydrolysis reaction on pretreated (acid pretreatment) wheat straw. 12,5mg (dry mass) of pretreated wheat straw is mixed with 0,0125mg of purified CBH1 and 40CBU Novo188 (Novozymes, Denmark) per mg of CBH1. 50mM sodium acetate (Sigma-Aldrich, Germany) is added up to 500µL. The assay is kept at temperatures ranging from 50°C to 65°C for 48 hours and analysed by HPLC to determine the temperature dependent glucose content.

SEQUENCE LISTING

50 **[0088]**

<110> Süd-Chemie AG

<120> optimized Cellulase Enzymes

55

<130> 139 202

<160> 41

EP 2 357 227 B1

<170> PatentIn version 3.4

<210> 1

<211> 1509

5 <212> DNA

<213> Artificial

<220>

10 <223> Coding Sequence for Talaromyces emersonii CBHI /Trichoderma reesei -CBD fusion (mature CBH-a)

<400> 1

```

cagcaggccg gcacggcgac ggcagagaac cccccgccc tgacatggca ggaatgcacc      60
15 gcccctggga gctgcaccac ccagaacggg gcggtcgttc ttgatgcgaa ctggcgttgg      120
gtgcacgatg tgaacggata caccaactgc tacacgggca atacctggga cccacgtac      180
tgccctgacg acgaaacctg cgcccagaac tgtgcgctgg acggcgcgga ttacgagggc      240
20 acctacggcg tgacttcgtc gggcagctcc ttgaaactca atttcgtcac cgggtcgaac      300
gtcggatccc gtctctacct gctgcaggac gactcgacct atcagatctt caagctcctg      360
aaccgcgagt tcagctttga cgtcgatgtc tccaatcttc cgtgcggatt gaacggcgct      420
25 ctgtactttg tcgccatgga cgccgacggc ggcgtgtcca agtaccgaa caacaaggct      480
ggtgccaaagt acggaaccgg gtattgcgac tcccaatgcc cacgggacct caagttcatc      540
gacggcgagg ccaacgtcga gggctggcag ccgtcttcga acaacgcca caccggaatt      600
30 ggcgaccacg gctcctgctg tgcggagatg gatgtctggg aagcaaacag catctccaat      660
gcggtcactc cgcacccgct cgacacgcca ggcagacga tgtgctctgg agatgactgc      720
ggtggcacat actetaacga tcgctacgcg ggaacctgcg atcctgacgg ctgtgacttc      780
35 aacccttacc gcatgggcaa cacttctttc tacgggcttg gcaagatcat cgataccacc      840
aagcccttca ctgtcgtgac gcagttcctc actgatgatg gtacggatac tggaaactctc      900
agcgagatca agcgtttcta catccagaac agcaacgtca ttccgcagcc caactcggac      960
40 atcagtggcg tgaccggcaa ctcgatcacg acggagttct gcaactgctca gaagcaggcc      1020
tttggcgaca cggacgactt ctctcagcac ggtggccttg ccaagatggg agcggccatg      1080
cagcagggta tggtcctggt gatgagtttg tgggacgact acgccgcgca gatgctgtgg      1140
45 ttggattccg actacccgac ggatgcggac cccacgacct ctggtattgc ccgtggaacg      1200
tgtccgacgg actcgggctg cccatcggat gtcgagtcgc agagcccca ctctacgtg      1260
acctactcga acattaagt tgggtccgat ggtagcacag gtaatccttc aggtggtaat      1320
50 cctccagggtg gaaacagagg aacaacgaca actagaagac cagctactac aactggttca      1380
agtccaggtc caactcaatc aactacgggt caatgtgggt gtataggtta ctctgggtccc      1440

actgtttgtg cttctggtac tacttgccaa gttctgaacc cttactactc acagtgtcta      1500
taatgataa                                         1509

```

EP 2 357 227 B1

<210> 2  
 <211> 500  
 <212> PRT  
 <213> Artificial

5

<220>  
 <223> Mature sequence of Talaromyces emersonii CBHI / Trichoderma reesei -CBD (mature CBH-a)

10

<400> 2

Gln Gln Ala Gly Thr Ala Thr Ala Glu Asn His Pro Pro Leu Thr Trp  
 1 5 10 15  
 Gln Glu Cys Thr Ala Pro Gly Ser Cys Thr Thr Gln Asn Gly Ala Val  
 20 25 30  
 Val Leu Asp Ala Asn Trp Arg Trp Val His Asp Val Asn Gly Tyr Thr  
 35 40 45  
 Asn Cys Tyr Thr Gly Asn Thr Trp Asp Pro Thr Tyr Cys Pro Asp Asp  
 50 55 60  
 Glu Thr Cys Ala Gln Asn Cys Ala Leu Asp Gly Ala Asp Tyr Glu Gly  
 65 70 75 80  
 Thr Tyr Gly Val Thr Ser Ser Gly Ser Ser Leu Lys Leu Asn Phe Val  
 85 90 95  
 Thr Gly Ser Asn Val Gly Ser Arg Leu Tyr Leu Leu Gln Asp Asp Ser  
 100 105 110  
 Thr Tyr Gln Ile Phe Lys Leu Leu Asn Arg Glu Phe Ser Phe Asp Val  
 115 120 125  
 Asp Val Ser Asn Leu Pro Cys Gly Leu Asn Gly Ala Leu Tyr Phe Val  
 130 135 140  
 Ala Met Asp Ala Asp Gly Gly Val Ser Lys Tyr Pro Asn Asn Lys Ala  
 145 150 155 160  
 Gly Ala Lys Tyr Gly Thr Gly Tyr Cys Asp Ser Gln Cys Pro Arg Asp  
 165 170 175  
 Leu Lys Phe Ile Asp Gly Glu Ala Asn Val Glu Gly Trp Gln Pro Ser  
 180 185 190  
 Ser Asn Asn Ala Asn Thr Gly Ile Gly Asp His Gly Ser Cys Cys Ala  
 195 200 205

55





EP 2 357 227 B1

atgtatcggg agttggccgt catctcggcc ttcttggcca cagctcgtgc tcagcaggcc 60  
 ggcacggcga cggcagagaa ccaccgccc ctgacatggc aggaatgcac cggccctggg 120  
 5 agctgcacca cccagaacgg ggcggtcggt cttgatgcga actggcgttg ggtgcacgat 180  
 gtgaacggat acaccaactg ctacacgggc aatacctggg accccacgta ctgccctgac 240  
 gacgaaacct gcgcccagaa ctgtgcgctg gacggcgcgg attacgaggg cacctacggc 300  
 10 gtgacttcgt cgggcagctc cttgaaactc aatttcgtca ccgggtcгаа cgtcggatcc 360  
 cgtctctacc tgctgcagga cgactcgacc tatcagatct tcaagctcct gaaccgagag 420  
 ttcagctttg acgtcgatgt ctccaatctt ccgtgcggat tgaacggcgc tctgtacttt 480  
 15 gtcgccatgg acgcccagcg cggcgtgtcc aagtaccgca acaacaaggc tggtgccaag 540  
 tacggaaccg ggtattgcga ctccaatgc ccacgggacc tcaagtcat cgacggcagag 600  
 gccaacgtcg agggctggca gccgtcttcg aacaacgcca acaccggaat tggcgaccac 660  
 20 ggctcctgct gtgcggagat ggatgtctgg gaagcaaaca gcatctcaa tgcggctact 720  
 ccgcacccgt gcgacacgcc aggccagacg atgtgctctg gagatgactg cggtggcaca 780  
 tactctaacg atcgctacgc gggaaactgc gatcctgacg gctgtgactt caacccttac 840  
 25 cgcatgggca acattcttt ctacggcctt ggcaagatca tcgataccac caagcccttc 900  
 actgtcgtga cgcagttcct cactgatgat ggtacggata ctggaactct cagcgagatc 960  
 aagcgttctt acatccagaa cagcaacgtc attccgcagc ccaactcgga catcagtggc 1020  
 30 gtgaccggca actcgatcac gacggagttc tgcactgctc agaagcaggc ctttggcgac 1080  
 acggacgact tctctcagca cggtagcctg gccaaagatgg gagcggccat gcagcagggt 1140  
 atggtcctgg tgatgagttt gtgggacgac tacgccgcgc agatgctgtg gttggattec 1200  
 35 gactaccgca cggatgcgga cccacgacc cctggtattg cccgtggaac gtgtccgacg 1260  
 gactcgggcg tccatcggga tgtcgagtgc cagagcccca actcctacgt gacctactcg 1320  
 aacattaagt ttggtccgat cggtagcaca ggtaatcctt cagggtgtaa tcctccaggt 1380  
 40 ggaaacagag gaacaacgac aactagaaga ccagctacta caactggttc aagtcaggt 1440  
 ccaactcaat cacactacgg tcaatgtggt ggtataggtt actctgggtcc cactgtttgt 1500  
 gcttctggta ctacttgcca agttctgaac ccttactact cacagtgtct agcttctgca 1560  
 45  
 catcatcacc accaccatta a 1581  
 50 <210> 4  
 <211> 70  
 <212> PRT  
 <213> Artificial  
 55 <220>  
 <223> Trichoderma reesei CBHI cellulose binding domain and linker sequence  
 <400> 4

EP 2 357 227 B1

1 Gly Ser Thr Gly Asn Pro Ser Gly Gly Asn Pro Pro Gly Gly Asn Arg  
 5 Gly Thr Thr Thr Thr Arg Arg Pro Ala Thr Thr Thr Gly Ser Ser Pro  
 10 Gly Pro Thr Gln Ser His Tyr Gly Gln Cys Gly Gly Ile Gly Tyr Ser  
 15 Gly Pro Thr Val Cys Ala Ser Gly Thr Thr Cys Gln Val Leu Asn Pro  
 Tyr Tyr Ser Gln Cys Leu

<210> 5

<211> 437

<212> PRT

<213> Artificial

<220>

<223> Talaromyces emersonii CBHI sequence (CBH-b)

<400> 5

30 Gln Gln Ala Gly Thr Ala Thr Ala Glu Asn His Pro Pro Leu Thr Trp  
 35 Gln Glu Cys Thr Ala Pro Gly Ser Cys Thr Thr Gln Asn Gly Ala Val  
 40 Val Leu Asp Ala Asn Trp Arg Trp Val His Asp Val Asn Gly Tyr Thr  
 45 Asn Cys Tyr Thr Gly Asn Thr Trp Asp Pro Thr Tyr Cys Pro Asp Asp  
 50 Glu Thr Cys Ala Gln Asn Cys Ala Leu Asp Gly Ala Asp Tyr Glu Gly  
 55 Thr Tyr Gly Val Thr Ser Ser Gly Ser Ser Leu Lys Leu Asn Phe Val  
 60 Thr Gly Ser Asn Val Gly Ser Arg Leu Tyr Leu Leu Gln Asp Asp Ser

EP 2 357 227 B1

			100					105				110				
5	Thr	Tyr	Gln 115	Ile	Phe	Lys	Leu	Leu 120	Asn	Arg	Glu	Phe	Ser 125	Phe	Asp	Val
	Asp	Val 130	Ser	Asn	Leu	Pro	Cys 135	Gly	Leu	Asn	Gly	Ala 140	Leu	Tyr	Phe	Val
10	Ala 145	Met	Asp	Ala	Asp	Gly 150	Gly	Val	Ser	Lys	Tyr 155	Pro	Asn	Asn	Lys	Ala 160
	Gly	Ala	Lys	Tyr	Gly 165	Thr	Gly	Tyr	Cys	Asp 170	Ser	Gln	Cys	Pro	Arg	Asp 175
15	Leu	Lys	Phe	Ile 180	Asp	Gly	Glu	Ala	Asn 185	Val	Glu	Gly	Trp	Gln 190	Pro	Ser
20	Ser	Asn	Asn 195	Ala	Asn	Thr	Gly	Ile 200	Gly	Asp	His	Gly	Ser 205	Cys	Cys	Ala
	Glu	Met 210	Asp	Val	Trp	Glu	Ala 215	Asn	Ser	Ile	Ser	Asn 220	Ala	Val	Thr	Pro
25	His 225	Pro	Cys	Asp	Thr	Pro 230	Gly	Gln	Thr	Met	Cys 235	Ser	Gly	Asp	Asp	Cys 240
30	Gly	Gly	Thr	Tyr	Ser 245	Asn	Asp	Arg	Tyr	Ala 250	Gly	Thr	Cys	Asp	Pro 255	Asp
	Gly	Cys	Asp	Phe 260	Asn	Pro	Tyr	Arg	Met 265	Gly	Asn	Thr	Ser	Phe 270	Tyr	Gly
35	Pro	Gly	Lys 275	Ile	Ile	Asp	Thr	Thr 280	Lys	Pro	Phe	Thr	Val 285	Val	Thr	Gln
40	Phe 290	Leu	Thr	Asp	Asp	Gly	Thr 295	Asp	Thr	Gly	Thr	Leu 300	Ser	Glu	Ile	Lys
	Arg 305	Phe	Tyr	Ile	Gln	Asn 310	Ser	Asn	Val	Ile	Pro 315	Gln	Pro	Asn	Ser	Asp 320
45	Ile	Ser	Gly	Val	Thr 325	Gly	Asn	Ser	Ile	Thr 330	Thr	Glu	Phe	Cys	Thr 335	Ala
50	Gln	Lys	Gln	Ala 340	Phe	Gly	Asp	Thr	Asp 345	Asp	Phe	Ser	Gln	His 350	Gly	Gly
	Leu	Ala	Lys 355	Met	Gly	Ala	Ala	Met 360	Gln	Gln	Gly	Met	Val 365	Leu	Val	Met
55	Ser	Leu 370	Trp	Asp	Asp	Tyr	Ala 375	Ala	Gln	Met	Leu	Trp 380	Leu	Asp	Ser	Asp

EP 2 357 227 B1

Tyr Pro Thr Asp Ala Asp Pro Thr Thr Pro Gly Ile Ala Arg Gly Thr  
385 390 395 400

5 Cys Pro Thr Asp Ser Gly Val Pro Ser Asp Val Glu Ser Gln Ser Pro  
405 410 415

10 Asn Ser Tyr Val Thr Tyr Ser Asn Ile Lys Phe Gly Pro Ile Asn Ser  
420 425 430

Thr Phe Thr Ala Ser  
435

15 <210> 6  
<211> 1590  
<212> DNA  
<213> Artificial

20 <220>  
<223> Coding sequence of Talaromyces emersonii CBHI fused to the alpha factor signal peptide

<400> 6

25

30

35

40

45

50

55

EP 2 357 227 B1

atgagatttc cttcaatttt tactgcagtt ttattcgcag catcctccgc attagctgct 60  
 ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggg 120  
 5 tacttagatt tagaagggga tttcgatggt gctgttttgc cattttccaa cagcacaat 180  
 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240  
 tctttggata aacgtgaggc ggaagcacc ctcagcagg ccggcacggc gacggcagag 300  
 10 aaccacccgc ccctgacatg gcaggaatgc accgcccctg ggagctgcac caccagaac 360  
 ggggcggtcg ttcttgatgc gaactggcgt tgggtgcacg atgtgaacgg atacaccaac 420  
 tgctacacgg gcaatacctg ggaccccacg tactgccctg acgacgaaac ctgcgcccag 480  
 15 aactgtgcmc tggacggcmc ggattacgag ggcacctacg gcgtgacttc gtcgggcagc 540  
 tccttgaaac tcaatttcgt caccgggtcg aacgtcggat cccgtctcta cctgctgcag 600  
 gacgactcga cctatcagat cttcaagctt ctgaaccgcg agttcagctt tgacgtcgat 660  
 20 gtctccaatc ttccgtgcgg attgaacggc gctctgtact ttgtcgccat ggacgccgac 720  
 ggcggcgtgt ccaagtaccc gaacaacaag gctggtgcc agtacggaac cgggtattgc 780  
 gactcccaat gccacggga cctcaagttc atcgacggcg aggccaacgt cgagggctgg 840  
 25 cagccgtctt cgaacaacgc caacaccgga attggcgacc acggctcctg ctgtgcggag 900  
 atggatgtct gggaagcaa cagcatctcc aatgcggtca ctccgcacc gtgagacacg 960  
 ccagccaga cgatgtgctc tggagatgac tgcggtggca catactctaa cgatcgctac 1020  
 30 gcgggaacct gcgacctga cggctgtgac ttcaaccctt accgcatggg caacacttct 1080  
 ttctacgggc ctggcaagat catcgatacc accaagccct tcaactgtcgt gacgcagttc 1140  
 ctcaactgat atggtacgga tactggaact ctcaagcaga tcaagcgtt ctacatccag 1200  
 35 aacagcaacg tcattccgca gcccaactcg gacatcagtg gcgtgaccgg caactcagtc 1260  
 acgacggagt tctgcactgc tcagaagcag gcctttggcg acacggacga cttctctcag 1320  
 40 cacggtggcc tggccaagat gggagcggcc atgcagcagg gtatggtcct ggtgatgagt 1380  
 ttgtgggacg actacgccgc gcagatgctg tggttggatt ccgactacc gacggatgag 1440  
 gacccacga cccctggtat tgcccgtgga acgtgtccga cggactcggg cgtcccatcg 1500  
 45 gatgtcgagt cgagagccc caactcctac gtgacctact cgaacattaa gtttggctccg 1560  
 atcaactcga ccttcaccgc ttcgtgataa 1590

<210> 7  
 <211> 429  
 50 <212> PRT  
 <213> Artificial

<220>  
 <223> Humicola grisea CBHI (CBH-d)  
 55  
 <400> 7

EP 2 357 227 B1

1 Gln Gln Ala Gly Thr Ile Thr Ala Glu Asn His Pro Arg Met Thr Trp  
 5 Lys Arg Cys Ser Gly Pro Gly Asn Cys Gln Thr Val Gln Gly Glu Val  
 10 Val Ile Asp Ala Asn Trp Arg Trp Leu His Asn Asn Gly Gln Asn Cys  
 15 Tyr Glu Gly Asn Lys Trp Thr Ser Gln Cys Ser Ser Ala Thr Asp Cys  
 20 Ala Gln Arg Cys Ala Leu Asp Gly Ala Asn Tyr Gln Ser Thr Tyr Gly  
 25 Ala Ser Thr Ser Gly Asp Ser Leu Thr Leu Lys Phe Val Thr Lys His  
 30 Glu Tyr Gly Thr Asn Ile Gly Ser Arg Phe Tyr Leu Met Ala Asn Gln  
 35 Asn Lys Tyr Gln Met Phe Thr Leu Met Asn Asn Glu Phe Ala Phe Asp  
 40 Val Asp Leu Ser Lys Val Glu Cys Gly Ile Asn Ser Ala Leu Tyr Phe  
 45 Val Ala Met Glu Glu Asp Gly Gly Met Ala Ser Tyr Pro Ser Asn Arg  
 50 Ala Gly Ala Lys Tyr Gly Thr Gly Tyr Cys Asp Ala Gln Cys Ala Arg  
 55 Asp Leu Lys Phe Ile Gly Gly Lys Ala Asn Ile Glu Gly Trp Arg Pro

EP 2 357 227 B1

180 185 190  
 5 Ser Thr Asn Asp Pro Asn Ala Gly Val Gly Pro Met Gly Ala Cys Cys  
 195 200 205  
 10 Ala Glu Ile Asp Val Trp Glu Ser Asn Ala Tyr Ala Tyr Ala Phe Thr  
 210 215 220  
 15 Pro His Ala Cys Gly Ser Lys Asn Arg Tyr His Ile Cys Glu Thr Asn  
 225 230 235 240  
 20 Asn Cys Gly Gly Thr Tyr Ser Asp Asp Arg Phe Ala Gly Tyr Cys Asp  
 245 250 255  
 25 Ala Asn Gly Cys Asp Tyr Asn Pro Tyr Arg Met Gly Asn Lys Asp Phe  
 260 265 270  
 30 Tyr Gly Lys Gly Lys Thr Val Asp Thr Asn Arg Lys Phe Thr Val Val  
 275 280 285  
 35 Ser Arg Phe Glu Arg Asn Arg Leu Ser Gln Phe Phe Val Gln Asp Gly  
 290 295 300  
 40 Arg Lys Ile Glu Val Pro Pro Pro Thr Trp Pro Gly Leu Pro Asn Ser  
 305 310 315 320  
 45 Ala Asp Ile Thr Pro Glu Leu Cys Asp Ala Gln Phe Arg Val Phe Asp  
 325 330 335  
 50 Asp Arg Asn Arg Phe Ala Glu Thr Gly Gly Phe Asp Ala Leu Asn Glu  
 340 345 350  
 55 Ala Leu Thr Ile Pro Met Val Leu Val Met Ser Ile Trp Asp Asp His  
 355 360 365  
 60 His Ser Asn Met Leu Trp Leu Asp Ser Ser Tyr Pro Pro Glu Lys Ala  
 370 375 380  
 65 Gly Leu Pro Gly Gly Asp Arg Gly Pro Cys Pro Thr Thr Ser Gly Val  
 385 390 395 400  
 70 Pro Ala Glu Val Glu Ala Gln Tyr Pro Asp Ala Gln Val Val Trp Ser  
 405 410 415  
 75 Asn Ile Arg Phe Gly Pro Ile Gly Ser Thr Val Asn Val  
 420 425

<210> 8

55 <211> 1563

<212> DNA

<213> Artificial

EP 2 357 227 B1

<220>

<223> Coding sequence of *Humicola grisea* CBHI fused to the alpha factor signal peptide

<400> 8

5  
 atgagatttc cttcaatfff tactgcagtt ttattcgcag catcctccgc attagctgct 60  
 ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggc 120  
 10 tacttagatt tagaagggga tttcgatggt gctgttttgc cattttccaa cagcacaat 180  
 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240  
 tctttggata aacgtgaggc ggaagcacc tctcagcagg ctggtactat tactgctgag 300  
 15 aaccacccaa gaatgacctg gaagagatgc tctggccag gaaactgtca gactgttcag 360  
 ggcgagggtg tgattgacgc taattggaga tggttgcaca acaacggcca gaactgttac 420  
 gagggtaaca agtggacctc tcagtgttct tctgctaccg actgtgctca gagatgtgct 480  
 20 ttggacggtg ccaactacca gtctacctac ggtgcttcta cctctgggta ctctctgacc 540  
 ctgaagttcg ttaccaagca cgagtacgga accaacatcg gctctagatt ctacctgatg 600  
 gccaacccaga acaagtacca gatgttcacc ctgatgaaca acgagttcgc ctttgacggt 660  
 25 gacctgtcta aggtggagtg cggatcaac tctgccctgt acttcggtgc tatggaagag 720  
 gacggtgaa tggcttctta cccatctaac agagccggtg ctaagtacgg tactggttac 780  
 tgtgacgcc agtgtgctag agacctgaag ttcacgggtg gaaaggcca cattgagggc 840  
 30 tggagaccat ctaccaacga cccaaacgct ggtgttggtc caatgggagc ttgttgtgcc 900  
 gagattgatg tgtgggagtc taacgcttac gcctacgctt ttacccaca cgcttgcggt 960  
 tctaagaaca gataccacat ctgcgagacc aacaactgtg gtggaaccta ctctgacgac 1020  
 35 agattcgtg gatactgca cgctaacggt tgtgactaca acccatacag aatgggcaac 1080  
 aaggacttct acggcaaggg aaagaccgtt gacaccaaca gaaagttcac cgtgggtgctc 1140  
 agattcgaga gaaacagact gtcgcagttc tttgtgcagg acggcagaaa gattgaggtc 1200  
 40 ccaccaccaa cttggccagg attgccaac tctgccgaca ttacccaga gttgtgtgac 1260  
 gctcagttca gagtgttcga cgacagaaac agatttgctg agaccggtgg ttttgacgct 1320  
 ttgaacgagg ctctgacat tccaatggtg ctggtgatgt ctatttggga cgaccaccac 1380  
 45 tctaacatgt tgtggctgga ctctcttac caaccagaga aggctggatt gccaggtggt 1440  
 gacagaggac catgtccaac tacttcgggt gttccagctg aggttgaggc tcagtacca 1500  
 gacgctcagg ttgtgtggtc gaacatcaga ttcggcccaa tccggttctac cgtgaacgtg 1560  
 50 taa 1563

<210> 9

<211> 439

<212> PRT

55 <213> Artificial

<220>

<223> *Thermoascus auratiacus* CBHI (CBH-e)

<400> 9

5

10

15

20

25

30

35

40

45

50

55

EP 2 357 227 B1

1 His Glu Ala Gly Thr Val Thr Ala Glu Asn His Pro Ser Leu Thr Trp  
 5 Gln Gln Cys Ser Ser Gly Gly Ser Cys Thr Thr Gln Asn Gly Lys Val  
 10 Val Ile Asp Ala Asn Trp Arg Trp Val His Thr Thr Ser Gly Tyr Thr  
 15 Val Thr Cys Ala Gln Asn Cys Ala Leu Asp Gly Ala Asp Tyr Ser Gly  
 20 Thr Tyr Gly Val Thr Thr Ser Gly Asn Ala Leu Arg Leu Asn Phe Val  
 25 Thr Gln Ser Ser Gly Lys Asn Ile Gly Ser Arg Leu Tyr Leu Leu Gln  
 30 Asp Asp Thr Thr Tyr Gln Ile Phe Lys Leu Leu Gly Gln Glu Phe Thr  
 35 Phe Asp Val Asp Val Ser Asn Leu Pro Cys Gly Leu Asn Gly Ala Leu  
 40 Tyr Phe Val Ala Met Asp Ala Asp Gly Asn Leu Ser Lys Tyr Pro Gly  
 45 Asn Lys Ala Gly Ala Lys Tyr Gly Thr Gly Tyr Cys Asp Ser Gln Cys  
 50 Pro Arg Asp Leu Lys Phe Ile Asn Gly Gln Ala Asn Val Glu Gly Trp  
 55 Gln Pro Ser Ala Asn Asp Pro Asn Ala Gly Val Gly Asn His Gly Ser  
 60 Ser Cys Ala Glu Met Asp Val Trp Glu Ala Asn Ser Ile Ser Thr Ala  
 65 Val Thr Pro His Pro Cys Asp Thr Pro Gly Gln Thr Met Cys Gln Gly  
 70 Asp Asp Cys Gly Gly Thr Tyr Ser Ser Thr Arg Tyr Ala Gly Thr Cys  
 75 Asp Thr Asp Gly Cys Asp Phe Asn Pro Tyr Gln Pro Gly Asn His Ser  
 80 Phe Tyr Gly Pro Gly Lys Ile Val Asp Thr Ser Ser Lys Phe Thr Val

EP 2 357 227 B1

		275				280					285					
5	Val	Thr	Gln	Phe	Ile	Thr	Asp	Asp	Gly	Thr	Pro	Ser	Gly	Thr	Leu	Thr
		290					295					300				
	Glu	Ile	Lys	Arg	Phe	Tyr	Val	Gln	Asn	Gly	Lys	Val	Ile	Pro	Gln	Ser
	305					310					315					320
10																
	Glu	Ser	Thr	Ile	Ser	Gly	Val	Thr	Gly	Asn	Ser	Ile	Thr	Thr	Glu	Tyr
					325					330					335	
15																
	Cys	Thr	Ala	Gln	Lys	Ala	Ala	Phe	Asp	Asn	Thr	Gly	Phe	Phe	Thr	His
				340					345					350		
	Gly	Gly	Leu	Gln	Lys	Ile	Ser	Gln	Ala	Leu	Ala	Gln	Gly	Met	Val	Leu
			355					360					365			
20																
	Val	Met	Ser	Leu	Trp	Asp	Asp	His	Ala	Ala	Asn	Met	Leu	Trp	Leu	Asp
		370					375					380				
25																
	Ser	Thr	Tyr	Pro	Thr	Asp	Ala	Asp	Pro	Asp	Thr	Pro	Gly	Val	Ala	Arg
	385					390					395					400
	Gly	Thr	Cys	Pro	Thr	Thr	Ser	Gly	Val	Pro	Ala	Asp	Val	Glu	Ser	Gln
					405					410					415	
30																
	Asn	Pro	Asn	Ser	Tyr	Val	Ile	Tyr	Ser	Asn	Ile	Lys	Val	Gly	Pro	Ile
				420					425					430		
35																
	Asn	Ser	Thr	Phe	Thr	Ala	Asn									
			435													

<210> 10

<211> 1593

<212> DNA

40 <213> Artificial

<220>

<223> coding sequence of Thermoascus auratiacus CBHI fused to the alpha factor signal peptide

45 <400> 10

50

55

EP 2 357 227 B1

atgagatttc cttcaatttt tactgcagtt ttattcgcag catcctccgc attagctgct 60  
 ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgatcatcgg 120  
 5 tacttagatt tagaaggggg tttcgcaggtt gctgttttgc cattttccaa cagcacaaaat 180  
 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240  
 tctttggata aacgtgaggc ggaagcacc tctcacgagg ccggtaccgt aaccgcagag 300  
 10 aatcaccctt ccctgacctg gcagcaatgc tccagcggcg gtagttgtac cacgcagaat 360  
 ggaaaagtgc ttatcgcagc gaactggcgt tgggtccata ccacctctgg atacaccaac 420  
 tgctacacgg gcaatacgtg ggacaccagt atctgtcccc acgacgtgac ctgctgctcag 480  
 15  
 aattgtgcct tggatggagc ggattacagt ggcacctatg gtgttacgac cagtggcaac 540  
 gccctgagac tgaactttgt cacccaaagc tcaggggaaga acattggctc gcgcctgtac 600  
 20 ctgctgcagg acgacaccac ttatcagatc ttcaagctgc tgggtcagga gtttaccttc 660  
 gatgtcgacg tctccaatct cccttgcggg ctgaacggcg ccctctactt tgtggccatg 720  
 gacgccgacg gcaatttgtc caaataccct ggcaacaagg caggcgctaa gtatggcact 780  
 25 ggttactgcg actctcagtg ccctcgggat ctcaagttca tcaacgggtca ggccaacggt 840  
 gaaggctggc agccgtctgc caacgaccca aatgccggcg ttggtaacca cggttcctcg 900  
 tgcgctgaga tggatgtctg ggaagccaac agcatctcta ctgcggtgac gcctcaccca 960  
 30 tgcgacaccc ccggccagac catgtgccag ggagacgact gtggtggaac ctactcctcc 1020  
 actcgcgatg ctggtacctg cgacactgat ggctgcgact tcaatcctta ccagccaggc 1080  
 aaccactcgt tctacggccc cgggaagatc gtcgacacta gctccaaatt caccgtcgtc 1140  
 35 acccagttca tcaccgacga cgggacaccc tccggcacc tgacggagat caaacgcttc 1200  
 tacgtccaga acggcaaggt gatccccag tcggagtcga cgatcagcgg cgtcaccggc 1260  
 aactcaatca ccaccgagta ttgcacggcc cagaaggcag ccttcgacaa caccggcttc 1320  
 40 ttcacgcacg gcgggcttca gaagatcagt caggctctgg ctcagggcat ggtcctcgtc 1380  
 atgagcctgt gggacgatca ccccgccaac atgctctggc tggacagcac ctaccgact 1440  
 gatgcggacc cggacacccc tggcgtcgcg cgcggtacct gccccacgac ctccggcgtc 1500  
 45 ccggccgacg tggagtcgca gaacccaat tcatatgtta tctactccaa catcaaggctc 1560  
 ggacccatca actcgacctt caccgccaac taa 1593

50 <210> 11  
 <211> 1794  
 <212> DNA  
 <213> Artificial

55 <220>  
 <223> Coding sequence for Trichoderma reesei CBHI (CBH-c), including the alpha factor signal peptide and a 6x His Tag

<400> 11

EP 2 357 227 B1

atgagatttc cttcaatttt tactgcagtt ttattcgag catcctccgc attagctgct 60  
 ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggt 120  
 5 tacttagatt tagaagggga tttcgatggt gctgttttgc cattttccaa cagcacaagt 180  
 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240  
 tctttggata aacgtgaggc ggaagcacc ctttcagctt gtacactgca atccgagact 300  
 10 catccacctt taacgtggca aaagtgtagt tctggcggaa cttgtactca acagactggt 360  
 agtgtcgtga tagatgctaa ctggagatgg acacatgcaa cgaactcctc aactaactgc 420  
 tacgatggta acacctggtc ttctacattg tgcctgaca acgaaacctg cgctaagaac 480  
 15 tgttgccttg atggagcagc ttacgcaagt acatatggtg tgactacctc tggtaacagc 540  
 ctttcattg gttttgtaac ccagtcggct cagaagaatg ttggtgctag attgtacctg 600  
  
 20 atggcttcag acaccacata ccaggagttt accttgttgg gaaacgagtt ctctttcgac 660  
 gtagatgtgt ctacagctacc atgtggattg aatggagcct tgtactttgt ctcaatggat 720  
 gcagacggag gtgtttcaaa gtaccctact aacacagctg gtgctaagta tggaaactgga 780  
 25 tactgcgatt ctcaatgccc aagagacctg aagtccatca acggacaagc taacgttgaa 840  
 ggttgggaac cttctagcaa caacgcaaac actggaattg gtggctatgg ttcttgcctg 900  
 tcagagatgg acatttggga agccaactcc atcagtgaag ctttgactcc acatccatgc 960  
 30 acaactgttg ggcaagaaat ttgcgaaggt gatgggtgtg gtggcactta ctctgataac 1020  
 agatacggcg gaacatgtga tccagatgga tgtgattgga acccatacag actgggtaac 1080  
 acttcgtttt acggaccagg ttcttccttc actctagaca ctacgaagaa gttgactgtg 1140  
 35 gtcaccaat ttgagacttc tgggtgccatt aaccgatact acgtgcagaa cggagttact 1200  
 ttccaacagc caaacgctga attgggtagt tactcaggca acgagcttaa cgatgactac 1260  
 tgcactgctg aagaagcaga atttgggtgga tcttcctttt cggataaggg tggattgacg 1320  
 40 cagttcaaga aagctacctc tgggtggaatg gttctagtca tgagtctgtg ggacgattac 1380  
 tacgctaaca tgctttggct ggactctact taccctacaa acgagacatc ttctactcct 1440  
 ggtgctgtaa gaggtagctg ttctacatct tctggagttc cagcccaagt tgagagtcaa 1500  
 45 agtccaaagt ccaaggtcac cttctccaac atcaagttcg gaccaattgg tagcacaggt 1560  
 aatccttcag gtggtaatcc tccaggtgga aacagaggaa caacgacaac tagaagacca 1620  
 gctactacaa ctggttcaag tccaggtcca actcaatcac actacggtca atgtgggtggt 1680  
 50 ataggttact ctggtccac tgtttgtgct tctggtacta cttgccaagt tctgaaccct 1740  
 tactactcac agtgtctagc ttctgcacac catcatcatc atcattaatg ataa 1794

55 <210> 12  
 <211> 496  
 <212> PRT  
 <213> Artificial

EP 2 357 227 B1

<220>

<223> Trichoderma reesei CBHI (CBH-C)

<400> 12

5

Gln Ser Ala Cys Thr Leu Gln Ser Glu Thr His Pro Pro Leu Thr Trp  
1 5 10 15

10

Gln Lys Cys Ser Ser Gly Gly Thr Cys Thr Gln Gln Thr Gly Ser Val  
20 25 30

15

Val Ile Asp Ala Asn Trp Arg Trp Thr His Ala Thr Asn Ser Ser Thr  
35 40 45

Asn Cys Tyr Asp Gly Asn Thr Trp Ser Ser Thr Leu Cys Pro Asp Asn  
50 55 60

20

Glu Thr Cys Ala Lys Asn Cys Cys Leu Asp Gly Ala Ala Tyr Ala Ser  
65 70 75 80

25

30

35

40

45

50

55

EP 2 357 227 B1

Thr Tyr Gly Val Thr Thr Ser Gly Asn Ser Leu Ser Ile Gly Phe Val  
 85 90 95  
 5 Thr Gln Ser Ala Gln Lys Asn Val Gly Ala Arg Leu Tyr Leu Met Ala  
 100 105 110  
 10 Ser Asp Thr Thr Tyr Gln Glu Phe Thr Leu Leu Gly Asn Glu Phe Ser  
 115 120 125  
 15 Phe Asp Val Asp Val Ser Gln Leu Pro Cys Gly Leu Asn Gly Ala Leu  
 130 135 140  
 Tyr Phe Val Ser Met Asp Ala Asp Gly Gly Val Ser Lys Tyr Pro Thr  
 145 150 155 160  
 20 Asn Thr Ala Gly Ala Lys Tyr Gly Thr Gly Tyr Cys Asp Ser Gln Cys  
 165 170 175  
 25 Pro Arg Asp Leu Lys Phe Ile Asn Gly Gln Ala Asn Val Glu Gly Trp  
 180 185 190  
 Glu Pro Ser Ser Asn Asn Ala Asn Thr Gly Ile Gly Gly His Gly Ser  
 195 200 205  
 30 Cys Cys Ser Glu Met Asp Ile Trp Glu Ala Asn Ser Ile Ser Glu Ala  
 210 215 220  
 35 Leu Thr Pro His Pro Cys Thr Thr Val Gly Gln Glu Ile Cys Glu Gly  
 225 230 235 240  
 Asp Gly Cys Gly Gly Thr Tyr Ser Asp Asn Arg Tyr Gly Gly Thr Cys  
 245 250 255  
 40 Asp Pro Asp Gly Cys Asp Trp Asn Pro Tyr Arg Leu Gly Asn Thr Ser  
 260 265 270  
 Phe Tyr Gly Pro Gly Ser Ser Phe Thr Leu Asp Thr Thr Lys Lys Leu  
 275 280 285  
 45 Thr Val Val Thr Gln Phe Glu Thr Ser Gly Ala Ile Asn Arg Tyr Tyr  
 290 295 300  
 50 Val Gln Asn Gly Val Thr Phe Gln Gln Pro Asn Ala Glu Leu Gly Ser  
 305 310 315 320  
 Tyr Ser Gly Asn Glu Leu Asn Asp Asp Tyr Cys Thr Ala Glu Glu Ala  
 325 330 335  
 55 Glu Phe Gly Gly Ser Ser Phe Ser Asp Lys Gly Gly Leu Thr Gln Phe  
 340 345 350

EP 2 357 227 B1

Lys Lys Ala Thr Ser Gly Gly Met Val Leu Val Met Ser Leu Trp Asp  
 355 360 365  
 5 Asp Tyr Tyr Ala Asn Met Leu Trp Leu Asp Ser Thr Tyr Pro Thr Asn  
 370 375 380  
 10 Glu Thr Ser Ser Thr Pro Gly Ala Val Arg Gly Ser Cys Ser Thr Ser  
 385 390 395  
 15 Ser Gly Val Pro Ala Gln Val Glu Ser Gln Ser Pro Asn Ala Lys Val  
 405 410  
 20 Thr Phe Ser Asn Ile Lys Phe Gly Pro Ile Gly Ser Thr Gly Asn Pro  
 420 425 430  
 25 Ser Gly Gly Asn Pro Pro Gly Gly Asn Arg Gly Thr Thr Thr Thr Arg  
 435 440 445  
 30 Arg Pro Ala Thr Thr Thr Gly Ser Ser Pro Gly Pro Thr Gln Ser His  
 450 455 460  
 35 Tyr Gly Gln Cys Gly Gly Ile Gly Tyr Ser Gly Pro Thr Val Cys Ala  
 465 470 475 480  
 40 Ser Gly Thr Thr Cys Gln Val Leu Asn Pro Tyr Tyr Ser Gln Cys Leu  
 485 490 495

<210> 13

<211> 1767

<212> DNA

<213> Artificial

<220>

<223> coding sequence for Trichoderma viride CBHI, including the alpha factor signal peptide

<400> 13

EP 2 357 227 B1

atgagatttc cttcaatttt tactgcagtt ttattcgcag catcctccgc attagctgct 60  
 ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggg 120  
 5 tacttagatt tagaagggga tttcgatggt gctgTTTTgc ctttttccaa cagcacaaat 180  
 aacggggttat tgTTTTataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240  
 tctttggata aacgtgaggc ggaagcacc tctcaatctg cttgcacctt gcagtctgaa 300  
 10 actcaccac cattgacctg gcagaagtgt tcttctggcg gtacttgtag tcagcagacc 360  
 ggttctggtg ttatcgacgc caactggaga tggactcacg ctaccaactc ttctaccaac 420  
 tgctacgacg gtaacacttg gtcgtctacc ttgtgtccag acaacgagac ctgtgccaag 480  
 15 aactgttgtt tggacgggac tgcttacgct tctacctacg gtgttaccac ctctggtaac 540  
 tcgctgtcta tcggtttctg taccagctc gccagaaaa atgttggtgc cagactgtac 600  
 ttgatggctt ctgacaaccac ctaccaagag tttaccctgc tgggtaacga gttctctttc 660  
 20  
 gacgtggacg tttctcaact gccatgtgga ctgaacggg cctgtactt cgtttctatg 720  
 gacgctgacg gtggtgtttc taagtaccca accaacaccg ctggtgctaa atacggaacc 780  
 25 ggttactgcg atttctcagtg cccaagagac ctgaagttca tcaacggaca ggctaacggt 840  
 gaaggatggg agccatcttc taacaacgcc aacaccggta ttggtggtca cggttcttgc 900  
 tgttctgaga tggacatctg ggaggccaac tctatttctg aggctttgac cccacacca 960  
 30 tgtactactg tgggtcaaga gatctgtgag ggtgatggtt gtggtggtac ttactcggac 1020  
 aacagatacg gtggtacttg tgaccagac ggttgtgatt gggaccata cagactgggt 1080  
 aacacctctt tctacggtcc aggatcttct tttaccctgg acaccaccaa gaagttgacc 1140  
 35 gttgttacc agtttgagac ctctgggccc atcaacagat actacgtgca gaacgggtgtt 1200  
 actttccagc agccaaacgc tgaactggga tcttactctg gtaacggact gaacgacgac 1260  
 tactgtactg ctgaggaagc tgagttcggg ggttcttctt tctctgacaa ggggtgactg 1320  
 40 acccagttta agaaggctac ctctggcgga atggtgctgg ttatgtcttt gtgggacgac 1380  
 tactacgcta acatgctgtg gcttgactct acctaccxaa ctaacgagac ctcttctacc 1440  
 ccagggtgctg ttagaggatc ttgctctacc tcttctggg ttcagctca ggttgagtct 1500  
 45 cagtctccaa acgccaaggt gaccttctct aacatcaagt tcgggtccaat cggttctact 1560  
 ggtgaccat ctggtggtaa cccaccaggt ggaaaccac ctggtactac cactaccaga 1620  
 agaccagcta ccaccactgg ttcttctcca ggtccaacc aatctcacta cggtcagtgt 1680  
 50 ggtggtattg gttactctgg tccaaccgtt tgtgcttctg gaaccacctg tcaggttctg 1740  
 aaccatact actcgcagtg cctgtaa 1767

55 <210> 14  
 <211> 497  
 <212> PRT  
 <213> Artificial

EP 2 357 227 B1

<220>

<223> Trichoderma viride CBHI (CBH-f)

<400> 14

5

Gln Ser Ala Cys Thr Leu Gln Ser Glu Thr His Pro Pro Leu Thr Trp  
1 5 10 15

10

Gln Lys Cys Ser Ser Gly Gly Thr Cys Thr Gln Gln Thr Gly Ser Val  
20 30

15

Val Ile Asp Ala Asn Trp Arg Trp Thr His Ala Thr Asn Ser Ser Thr  
35 40 45

Asn Cys Tyr Asp Gly Asn Thr Trp Ser Ser Thr Leu Cys Pro Asp Asn  
50 55 60

20

Glu Thr Cys Ala Lys Asn Cys Cys Leu Asp Gly Ala Ala Tyr Ala Ser  
65 70 75 80

25

30

35

40

45

50

55

EP 2 357 227 B1

Thr Tyr Gly Val Thr Thr Ser Gly Asn Ser Leu Ser Ile Gly Phe Val  
 85 90 95  
 5 Thr Gln Ser Ala Gln Lys Asn Val Gly Ala Arg Leu Tyr Leu Met Ala  
 100 105 110  
 Ser Asp Thr Thr Tyr Gln Glu Phe Thr Leu Leu Gly Asn Glu Phe Ser  
 115 120 125  
 10 Phe Asp Val Asp Val Ser Gln Leu Pro Cys Gly Leu Asn Gly Ala Leu  
 130 135 140  
 Tyr Phe Val Ser Met Asp Ala Asp Gly Gly Val Ser Lys Tyr Pro Thr  
 145 150 155 160  
 Asn Thr Ala Gly Ala Lys Tyr Gly Thr Gly Tyr Cys Asp Ser Gln Cys  
 165 170 175  
 20 Pro Arg Asp Leu Lys Phe Ile Asn Gly Gln Ala Asn Val Glu Gly Trp  
 180 185 190  
 Glu Pro Ser Ser Asn Asn Ala Asn Thr Gly Ile Gly Gly His Gly Ser  
 195 200 205  
 25 Cys Cys Ser Glu Met Asp Ile Trp Glu Ala Asn Ser Ile Ser Glu Ala  
 210 215 220  
 Leu Thr Pro His Pro Cys Thr Thr Val Gly Gln Glu Ile Cys Glu Gly  
 225 230 235 240  
 Asp Gly Cys Gly Gly Thr Tyr Ser Asp Asn Arg Tyr Gly Gly Thr Cys  
 245 250 255  
 35 Asp Pro Asp Gly Cys Asp Trp Asp Pro Tyr Arg Leu Gly Asn Thr Ser  
 260 265 270  
 Phe Tyr Gly Pro Gly Ser Ser Phe Thr Leu Asp Thr Thr Lys Lys Leu  
 275 280 285  
 Thr Val Val Thr Gln Phe Glu Thr Ser Gly Ala Ile Asn Arg Tyr Tyr  
 290 295 300  
 45 Val Gln Asn Gly Val Thr Phe Gln Gln Pro Asn Ala Glu Leu Gly Ser  
 305 310 315 320  
 Tyr Ser Gly Asn Gly Leu Asn Asp Asp Tyr Cys Thr Ala Glu Glu Ala  
 325 330 335  
 Glu Phe Gly Gly Ser Ser Phe Ser Asp Lys Gly Gly Leu Thr Gln Phe  
 340 345 350  
 55 Lys Lys Ala Thr Ser Gly Gly Met Val Leu Val Met Ser Leu Trp Asp



EP 2 357 227 B1

atgagatttc cttcaatfff tactgcagtt ttattcgcag catcctccgc attagctgct 60  
 ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggc 120  
 5 tacttagatt tagaagggga tttcgatggt gctgttttgc cattttccaa cagcacaat 180  
 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240  
 tctttggata aacgtgaggc ggaagcatgc tcgcagcagg ctggtacaat tactgctgag 300  
 10 aaccatccaa gaatgacgtg gaagagatgt agtgggccag gaaactgtca gactgttcag 360  
 ggtgaggctg tgatagatgc taactggaga tggttgcata acaacggcca gaactgctac 420  
 gagggtaaca agtggacctc tcagtgttct tctgctaccg actgcgctca gagatgtgct 480  
 15 cttgatggag caaactacca gagtacatat ggtgcttcta cctctgggtga cagccttacc 540  
 ctgaagtttg taaccaagca cgagtacgga accaatatcg gttctagatt ctacctgatg 600  
  
 20 gctaaccaga acaagtacca gatgtttacc ttgatgaaca acgagttcgc cttcgacgta 660  
 gatctgtcta aggtggagtg tggaaatcaat tctgccttgt actttgtcgc tatggaagag 720  
 gacggaggta tggcttctta cccttctaac agagctgggtg ctaagtatgg aactggatac 780  
 25 tgcgatgcc aatgcgctag agacctgaag ttcacggtg gaaaggctaa cattgaaggt 840  
 tggagacctt ctaccaacga cccaaacgct ggagttggtc caatgggtgc ttgctgtgcc 900  
 gagattgacg tgtgggaatc taacgcttac gcctacgctt ttactccaca tgcttgcggc 960  
 30 tctaagaaca gataccacat ttgcgaaacc aacaactgtg gtggcactta ctctgatgac 1020  
 agattcgctg gatactgtga tgctaacgga tgtgattaca acccatacag aatgggtaac 1080  
 aaggactttt acggaaaggg taagactggt gacactaaca gaaagttcac tgtggctctg 1140  
 35 agatttgaga gaaacagact gtcgcagttc tttgtgcagg acggaagaaa gattgaggtc 1200  
 ccaccaccaa cttggccagg attgccaaac tctgccgaca ttaccccaga gttgtgacgac 1260  
 gctcagttca gagtgtttga cgacagaaac agatttgctg agaccgggtg atttgacgct 1320  
 40 ttgaacgagg ctctgaccat tccaatggtt ctagtcatga gtatttggga cgatcaccac 1380  
 tctaacatgc tttggctgga ctcttcttac cctccagaga aggctggatt gcctgggtggt 1440  
 gacagaggtc catgtccaac aacttctgga gttccagccg aggttgaggc tcaataccca 1500  
 45 gacgcccagg tctgtgtggt caacatcaga ttcggaccaa ttggaagctt aacaggtaat 1560  
 ccttcagggt gtaatcctcc aggtggaaac agaggaacaa cgacaactag aagaccagct 1620  
 actacaactg gttcaagtcc aggtccaact caatcacact acggtcaatg tgggtgtata 1680  
 50 ggttactctg gtcccactgt ttgtgcttct ggtactactt gccaagttct gaacccttac 1740  
 tactcacagt gtctagcttc tgcacaccat catcatcatc attaa 1785  
  
 55 <210> 16  
 <211> 503  
 <212> PRT  
 <213> Artificial

EP 2 357 227 B1

<220>

<223> Humicola grisea CBHI- Trichoderma reesei CBHI cellulose binding domain fusion protein including a 6x His Tag (CBH-g)

5 <400> 16

Gln Gln Ala Gly Thr Ile Thr Ala Glu Asn His Pro Arg Met Thr Trp  
1 5 10 15

10

Lys Arg Cys Ser Gly Pro Gly Asn Cys Gln Thr Val Gln Gly Glu Val  
20 25 30

15

Val Ile Asp Ala Asn Trp Arg Trp Leu His Asn Asn Gly Gln Asn Cys  
35 40 45

20

Tyr Glu Gly Asn Lys Trp Thr Ser Gln Cys Ser Ser Ala Thr Asp Cys  
50 55 60

25

30

35

40

45

50

55

EP 2 357 227 B1

Ala Gln Arg Cys Ala Leu Asp Gly Ala Asn Tyr Gln Ser Thr Tyr Gly  
65 70 75 80

5 Ala Ser Thr Ser Gly Asp Ser Leu Thr Leu Lys Phe Val Thr Lys His  
85 90 95

Glu Tyr Gly Thr Asn Ile Gly Ser Arg Phe Tyr Leu Met Ala Asn Gln  
100 105 110

10 Asn Lys Tyr Gln Met Phe Thr Leu Met Asn Asn Glu Phe Ala Phe Asp  
115 120 125

15 Val Asp Leu Ser Lys Val Glu Cys Gly Ile Asn Ser Ala Leu Tyr Phe  
130 135 140

Val Ala Met Glu Glu Asp Gly Gly Met Ala Ser Tyr Pro Ser Asn Arg  
145 150 155 160

20 Ala Gly Ala Lys Tyr Gly Thr Gly Tyr Cys Asp Ala Gln Cys Ala Arg  
165 170 175

25 Asp Leu Lys Phe Ile Gly Gly Lys Ala Asn Ile Glu Gly Trp Arg Pro  
180 185 190

Ser Thr Asn Asp Pro Asn Ala Gly Val Gly Pro Met Gly Ala Cys Cys  
195 200 205

30 Ala Glu Ile Asp Val Trp Glu Ser Asn Ala Tyr Ala Tyr Ala Phe Thr  
210 215 220

35 Pro His Ala Cys Gly Ser Lys Asn Arg Tyr His Ile Cys Glu Thr Asn  
225 230 235 240

Asn Cys Gly Gly Thr Tyr Ser Asp Asp Arg Phe Ala Gly Tyr Cys Asp  
245 250 255

40 Ala Asn Gly Cys Asp Tyr Asn Pro Tyr Arg Met Gly Asn Lys Asp Phe  
260 265 270

Tyr Gly Lys Gly Lys Thr Val Asp Thr Asn Arg Lys Phe Thr Val Val  
275 280 285

45 Ser Arg Phe Glu Arg Asn Arg Leu Ser Gln Phe Phe Val Gln Asp Gly  
290 295 300

50 Arg Lys Ile Glu Val Pro Pro Pro Thr Trp Pro Gly Leu Pro Asn Ser  
305 310 315 320

Ala Asp Ile Thr Pro Glu Leu Cys Asp Ala Gln Phe Arg Val Phe Asp  
325 330 335

55 Asp Arg Asn Arg Phe Ala Glu Thr Gly Gly Phe Asp Ala Leu Asn Glu

EP 2 357 227 B1

340 345 350

5 Ala Leu Thr Ile Pro Met Val Leu Val Met Ser Ile Trp Asp Asp His  
355 360 365

His Ser Asn Met Leu Trp Leu Asp Ser Ser Tyr Pro Pro Glu Lys Ala  
370 375 380

10 Gly Leu Pro Gly Gly Asp Arg Gly Pro Cys Pro Thr Thr Ser Gly Val  
385 390 395 400

15 Pro Ala Glu Val Glu Ala Gln Tyr Pro Asp Ala Gln Val Val Trp Ser  
405 410 415

Asn Ile Arg Phe Gly Pro Ile Gly Ser Leu Thr Gly Asn Pro Ser Gly  
420 425 430

20 Gly Asn Pro Pro Gly Gly Asn Arg Gly Thr Thr Thr Thr Arg Arg Pro  
435 440 445

25 Ala Thr Thr Thr Gly Ser Ser Pro Gly Pro Thr Gln Ser His Tyr Gly  
450 455 460

Gln Cys Gly Gly Ile Gly Tyr Ser Gly Pro Thr Val Cys Ala Ser Gly  
465 470 475 480

30 Thr Thr Cys Gln Val Leu Asn Pro Tyr Tyr Ser Gln Cys Leu Ala Ser  
485 490 495

35 Ala His His His His His His  
500

<210> 17

<211> 1809

<212> DNA

40 <213> Artificial

<220>

<223> Coding sequence for Talaromyces emersonii CBHI / Trichoderma reesei -CBD fusion including the alpha factor signal peptide and a 6x His Tag

45

<400> 17

50

55

EP 2 357 227 B1

atgagatttc cttcaatddd tactgcagtt ttattcgcag catcctccgc attagctgct 60  
 ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgatcatcgg 120  
 5 tacttagatt tagaaggggga tttcagatgtt gctgttttgc cattttccaa cagcacaaat 180  
 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240  
 tctttggata aacgtgaggc ggaagcatgc tcgcagcagg ccggcacggc gacggcagag 300  
 10 aaccacccgc ccctgacatg gcaggaatgc accgcccctg ggagctgcac caccagaac 360  
 ggggcggctg ttcttgatgc gaactggcgt tgggtgcacg atgtgaacgg atacaccaac 420  
 tgctacacgg gcaatacctg ggaccccacg tactgccctg acgacgaaac ctgcgcccag 480  
 15  
 aactgtgcgc tggacggcgc ggattacgag ggcaectacg gcgtgacttc gtcgggcagc 540  
 tccttgaaac tcaattdcgt caccgggtcg aacgtcggat cccgtctcta cctgctgcag 600  
 20 gacgactcga cctatcagat cttcaagctc ctgaaccgcg agttcagctt tgacgtcgat 660  
 gtctccaatc ttccgtgcgg attgaacggc gctctgtact ttgtcgccat ggacgccgac 720  
 ggcggcgtgt ccaagtaccc gaacaacaag gctggtgcca agtacggaac cgggtattgc 780  
 25 gactcccaat gcccacggga cctcaagttc atcgcggcg aggccaacgt cgagggctgg 840  
 cagccgtctt cgaacaacgc caacaccgga attggcgacc acggctctcg ctgtgcggag 900  
 atggatgtct ggggaagcaaa cagcatctcc aatgcgggtca ctccgcaccc gtgcgacacg 960  
 30 ccagccaga cgatgtgctc tggagatgac tgcggtggca catactctaa cgatcgetac 1020  
 gcgggaaact gcgatcctga cggctgtgac ttcaaccctt accgcatggg caacacttct 1080  
 ttctacgggc ctggcaagat catcgatacc accaagccct tcaactgtcgt gacgcagttc 1140  
 35 ctcaactgatg atggtacgga tactggaact ctacgcgaga tcaagcgtt ctacatccag 1200  
 aacagcaacg tcattccgca gcccaactcg gacatcagtg gcgtgaccgg caactcgatc 1260  
 acgacggagt tctgcactgc tcagaagcag gcctttggcg acacggacga cttctctcag 1320  
 40 cacgggtggc tggccaagat gggagcggcc atgcagcagg gtatggtcct ggtgatgagt 1380  
 ttgtgggacg actacgccgc gcagatgctg tggttggatt ccgactaccc gacggatgcg 1440  
 gaccccacga cccctggtat tgcccgtgga acgtgtccga cggactcggg cgtcccatcg 1500  
 45 gatgtcagat cgcagagccc caactcctac gtgacctact cgaacattaa gtttgggtccg 1560  
 atcggtagca caggtaatcc ttcaggtggt aatcctccag gtggaaacag aggaacaacg 1620  
 acaactagaa gaccagctac tacaactggt tcaagtccag gtccaactca atcacactac 1680  
 50 ggtcaatgtg gtggtatagg ttactctggt cccactgttt gtgcttctgg tactacttgc 1740  
 caagttctga acccttacta ctacagtggt ctagcttctg cacatcatca ccaccacat 1800  
 taatgataa 1809  
 55  
 <210> 18  
 <211> 509  
 <212> PRT

EP 2 357 227 B1

<213> Artificial

<220>

<223> Mature Sequence of Talaromyces emersonii CBHI / Trichoderma reesei -CBD fusion with 6x-His tag (CBH-ah)

5

<400> 18

10 Gln Gln Ala Gly Thr Ala Thr Ala Glu Asn His Pro Pro Leu Thr Trp  
1 5 10  
15 Gln Glu Cys Thr Ala Pro Gly Ser Cys Thr Thr Gln Asn Gly Ala Val  
20 25 30  
25 Val Leu Asp Ala Asn Trp Arg Trp Val His Asp Val Asn Gly Tyr Thr  
35 40 45

20

25

30

35

40

45

50

55

EP 2 357 227 B1

Asn Cys Tyr Thr Gly Asn Thr Trp Asp Pro Thr Tyr Cys Pro Asp Asp  
 50 55 60  
 5 Glu Thr Cys Ala Gln Asn Cys Ala Leu Asp Gly Ala Asp Tyr Glu Gly  
 65 70 75 80  
 Thr Tyr Gly Val Thr Ser Ser Gly Ser Ser Leu Lys Leu Asn Phe Val  
 85 90  
 10 Thr Gly Ser Asn Val Gly Ser Arg Leu Tyr Leu Leu Gln Asp Asp Ser  
 100 105 110  
 15 Thr Tyr Gln Ile Phe Lys Leu Leu Asn Arg Glu Phe Ser Phe Asp Val  
 115 120 125  
 Asp Val Ser Asn Leu Pro Cys Gly Leu Asn Gly Ala Leu Tyr Phe Val  
 130 135 140  
 20 Ala Met Asp Ala Asp Gly Gly Val Ser Lys Tyr Pro Asn Asn Lys Ala  
 145 150 155 160  
 25 Gly Ala Lys Tyr Gly Thr Gly Tyr Cys Asp Ser Gln Cys Pro Arg Asp  
 165 170 175  
 30 Leu Lys Phe Ile Asp Gly Glu Ala Asn Val Glu Gly Trp Gln Pro Ser  
 180 185 190  
 Ser Asn Asn Ala Asn Thr Gly Ile Gly Asp His Gly Ser Cys Cys Ala  
 195 200 205  
 35 Glu Met Asp Val Trp Glu Ala Asn Ser Ile Ser Asn Ala Val Thr Pro  
 210 215 220  
 40 His Pro Cys Asp Thr Pro Gly Gln Thr Met Cys Ser Gly Asp Asp Cys  
 225 230 235 240  
 Gly Gly Thr Tyr Ser Asn Asp Arg Tyr Ala Gly Thr Cys Asp Pro Asp  
 245 250 255  
 45 Gly Cys Asp Phe Asn Pro Tyr Arg Met Gly Asn Thr Ser Phe Tyr Gly  
 260 265 270  
 50 Pro Gly Lys Ile Ile Asp Thr Thr Lys Pro Phe Thr Val Val Thr Gln  
 275 280 285  
 Phe Leu Thr Asp Asp Gly Thr Asp Thr Gly Thr Leu Ser Glu Ile Lys  
 290 295 300  
 55 Arg Phe Tyr Ile Gln Asn Ser Asn Val Ile Pro Gln Pro Asn Ser Asp  
 305 310 315 320

EP 2 357 227 B1

Ile Ser Gly Val Thr Gly Asn Ser Ile Thr Thr Glu Phe Cys Thr Ala  
 325 330 335

5 Gln Lys Gln Ala Phe Gly Asp Thr Asp Asp Phe Ser Gln His Gly Gly  
 340 345

10 Leu Ala Lys Met Gly Ala Ala Met Gln Gln Gly Met Val Leu Val Met  
 355 360 365

Ser Leu Trp Asp Asp Tyr Ala Ala Gln Met Leu Trp Leu Asp Ser Asp  
 370 375 380

15 Tyr Pro Thr Asp Ala Asp Pro Thr Thr Pro Gly Ile Ala Arg Gly Thr  
 385 390 395 400

20 Cys Pro Thr Asp Ser Gly Val Pro Ser Asp Val Glu Ser Gln Ser Pro  
 405 410 415

Asn Ser Tyr Val Thr Tyr Ser Asn Ile Lys Phe Gly Pro Ile Gly Ser  
 420 425 430

25 Thr Gly Asn Pro Ser Gly Gly Asn Pro Pro Gly Gly Asn Arg Gly Thr  
 435 440 445

30 Thr Thr Thr Arg Arg Pro Ala Thr Thr Thr Gly Ser Ser Pro Gly Pro  
 450 455 460

35 Thr Gln Ser His Tyr Gly Gln Cys Gly Gly Ile Gly Tyr Ser Gly Pro  
 465 470 475 480

Thr Val Cys Ala Ser Gly Thr Thr Cys Gln Val Leu Asn Pro Tyr Tyr  
 485 490 495

40 Ser Gln Cys Leu Ala Ser Ala His His His His His  
 500 505

<210> 19

<211> 1335

<212> DNA

45 <213> Artificial

<220>

<223> Alternative coding sequence of Humicola grisea CBHI with signal sequence

50 <400> 19

55

EP 2 357 227 B1

atggccagcg atctggcaca gcaggctggt acaattactg ctgagaacca tccaagaatg 60  
 acgtggaaga gatgtagtgg tccaggaaac tgtcagactg ttcagggtga ggtcgtgata 120  
 5 gatgctaact ggagatggtt gcataacaac ggccagaact gctacgaggg taacaagtgg 180  
 acctctcagt gttcttctgc taccgactgc gctcagagat gtgctcttga tggagcaaac 240  
 taccagagta catatggtgc ttctacctct ggtgacagcc ttaccctgaa gtttgaacc 300  
 10 aagcacgagt acggaaccaa tatcggttct agattctacc tgatggctaa ccagaacaag 360  
 taccagatgt ttaccttgat gaacaacgag ttcgccttcg acgtagatct gtctaagggtg 420  
 15 gagtgtggaa tcaattctgc cttgtacttt gtcgctatgg aagaggacgg aggtatggct 480  
 tcttaccctt ctaacagagc tggtgctaag tatggaactg gatactgcca tgcccaatgc 540  
 gctagagacc tgaagttcat cggtggaag gctaacattg aaggttggag accttctacc 600  
 20 aacgacccaa acgctggagt tggccaatg ggtgcttgct gtgccgagat tgacgtgtgg 660  
 gaatctaacg cttacgccta cgcttttact ccacatgctt gcggttctaa gaacagatac 720  
 cacatttgcg aaaccaacaa ctgtggtggc acttactctg atgacagatt cgctggatac 780  
 25 tgtgatgcta acggatgtga ttacaacca tacagaatgg gtaacaagga cttttacgga 840  
 aagggtaaga ctgttgacac taacagaaag ttcactgtgg tctcgagatt tgagagaaac 900  
 agactgtcgc agttctttgt gcaggacgga agaaagattg aggtcccacc accaacttgg 960  
 30 ccaggattgc caaactctgc cgacattacc ccagagttgt gcgacgctca gttcagagtg 1020  
 tttgacgaca gaaacagatt tgctgagacc ggtggatttg acgctttgaa cgaggctctg 1080  
 accattccaa tggttctagt catgagtatt tgggacgatc accactctaa catgctttgg 1140  
 35 ctggactctt cttaccctcc agagaaggct ggattgcctg gtggtgacag aggtccatgt 1200  
 ccaacaactt ctggagttcc agccgagggt gaggtcaat acccagacgc ccaggtcgtg 1260  
 tggccaaca tcagattcgg accaattggg agcacagtga atgtggcttc tgcacaccat 1320  
 40 catcatcatc attga 1335

<210> 20

<211> 41

<212> DNA

45 <213> Artificial

<220>

<223> Primer forward

50 <400> 20

gaggcgaag caccctca atctgctgc acctgcagt c 41

<210> 21

<211> 38

55 <212> DNA

<213> Artificial

<220>

EP 2 357 227 B1

<223> Primer reverse

<400> 21  
5 ggagacgcag agcccttatt acaggcactg cgagtagt 38

<210> 22  
<211> 41  
<212> DNA  
<213> Artificial

10 <220>  
<223> Primer forward

<400> 22  
15 gaggcggaag cacccttca gcaggctggt actattactg c 41

<210> 23  
<211> 44  
<212> DNA  
20 <213> Artificial

<220>  
<223> Primer reverse

25 <400> 23  
ggagacgcag agcccttaca cggtcacggt agaaccgatt gggc 44

<210> 24  
<211> 41  
30 <212> DNA  
<213> Artificial

<220>  
<223> Primer forward

35 <400> 24  
gaggcggaag cacccttca cgaggccggt accgtaaccg c 41

<210> 25  
40 <211> 41  
<212> DNA  
<213> Artificial

<220>  
45 <223> Primer reverse

<400> 25  
ggagacgcag agcccttatt agttggcggg gaaggtcgag t 41

<210> 26  
50 <211> 41  
<212> DNA  
<213> Artificial

55 <220>  
<223> Primer forward

<400> 26

EP 2 357 227 B1

gaggcggaag caccctctca gcaggcggc acggcgacgg c 41

<210> 27  
<211> 41  
5 <212> DNA  
<213> Artificial

<220>  
<223> Primer reverse

10

<400> 27  
ggagacgcag agcccttatc acgaagcggg gaaggtcgag t 41

<210> 28  
15 <211> 41  
<212> DNA  
<213> Artificial

<220>  
20 <223> Primer forward

<400> 28  
gaggcggaag caccctctca gcaggcggc acggcgacgg c 41

25 <210> 29  
<211> 38  
<212> DNA  
<213> Artificial

30 <220>  
<223> Primer reverse

<400> 29  
35 attacctgtg ctaccgatcg gaccaaactt aatgttcg 38

<210> 30  
<211> 38  
<212> DNA  
<213> Artificial

40 <220>  
<223> Primer forward

<400> 30  
45 aagtttggtc cgatcggtag cacaggaat ccttcagg 38

<210> 31  
<211> 44  
<212> DNA  
50 <213> Artificial

<220>  
<223> Primer reverse

55 <400> 31  
ggagacgcag agcccttatt atagacactg tgagtagtaa ggg t 44

<210> 32

EP 2 357 227 B1

<211> 41  
<212> DNA  
<213> Artificial

5 <220>  
<223> Primer forward

<400> 32  
gaggcgaag caccctctca gcaggccggc acggcgacggc 41

10 <210> 33  
<211> 44  
<212> DNA  
<213> Artificial

15 <220>  
<223> Primer reverse

<400> 33  
20 ggagacgcag agccctatc attaatggtg gtggtgatga tgag 44

<210> 34  
<211> 40  
<212> DNA  
25 <213> Artificial

<220>  
<223> Primer forward

30 <400> 34  
aggcgaagc atgctcgag caggctggtg caattactgc 40

<210> 35  
<211> 41  
35 <212> DNA  
<213> Artificial

<220>  
<223> Primer reverse

40 <400> 35  
ggattactg ttaagctcc aatggtccg aatctgatg t 41

<210> 36  
45 <211> 42  
<212> DNA  
<213> Artificial

<220>  
50 <223> Primer forward

<400> 36  
accaattgga agctaacag gtaatcctc aggtgtaat cc 42

55 <210> 37  
<211> 46  
<212> DNA  
<213> Artificial

## EP 2 357 227 B1

<220>

<223> Primer reverse

<400> 37

5 atcttcgagg tcgacttatac attaatgatg atgatgatgg tgtgca 46

<210> 38

<211> 40

<212> DNA

10 <213> Artificial

<220>

<223> Primer forward

<400> 38

15 aggcggaagc atgctcgag caggctggta caattactgc 40

<210> 39

<211> 46

20 <212> DNA

<213> Artificial

<220>

<223> Primer reverse

25

<400> 39

atcttcgagg tcgacttatac attaatgatg atgatgatgg tgtgca 46

<210> 40

30 <211> 21

<212> DNA

<213> Artificial

<220>

35 <223> oligonucleotide alpha-f

<400> 40

tactattgcc agcattgctg c 21

40

<210> 41

<211> 23

<212> DNA

<213> Artificial

45

<220>

<223> Oligonucleotide oli740

<400> 41

50 tcagctattt cacatacaaa tog 23

### Claims

1. A polypeptide having cellobiohydrolase activity, wherein the polypeptide comprises an amino acid sequence having at least 85 % sequence identity to SEQ ID NO: 2, wherein the amino acid residue at position Q1 of SEQ ID NO: 2 is modified by substitution or deletion.
2. The polypeptide according to claim 1, wherein the polypeptide maintains 50 % of its maximum substrate conversion

**EP 2 357 227 B1**

capacity when the conversion is done for 60 minutes at a temperature of 60°C or higher.

3. The polypeptide according to claim 1 or 2, wherein the polypeptide comprises an amino acid sequence having at least 90 %, preferably at least 95 %, more preferably at least 99 % sequence identity to SEQ ID NO: 2.
4. The polypeptide according to one or more of the preceding claims, wherein the amino acid sequence of the polypeptide has the sequence as defined by SEQ ID NO: 2, or a sequence as defined by SEQ ID NO: 2 wherein 1 to 75 amino acid residues, more preferably 1 to 35 amino acid residues are substituted, deleted, or inserted.
5. The polypeptide according to claim 4, wherein additionally one or more of the following amino acid residues of the sequence defined by SEQ ID NO: 2 are modified by substitution or deletion: positions G4, A6, T15, Q28, W40, D64, E65, A72, S86, K92, V130, V152, Y155, K159, D181, E183, N194, D202, P224, T243, Y244, I277, K304, N310, S311, N318, D320, T335, T344, D346, Q349, A358, Y374, A375, T392, T393, D410, Y422, P442, N445, R446, T456, S460, P462, G463, H468 and/or V482 of amino acids 1 to 500 of SEQ ID NO: 2.
6. The polypeptide according to claim 5, wherein the polypeptide comprises one or more of the following preferred exchanges with respect to the sequence defined by SEQ ID NO: 2:

Position	Preferred Exchange
Q1	L
G4	C
A6	G,V
T15	S
Q28	Q,R
W40	R
D64	N
E65	K,V
A72	C,V
S86	T
K92	K,R
V130	I,V
V152	A,E
Y155	C
K159	E
D181	N
E183	V,K
N194	C,R,Y,D,K,I,L,G,Q,S,V
D202	Y,N,G
P224	L
T243	I,C,R,Y,A,F,Q,P,D,V,W,L,M
Y244	F,H
I277	V
K304	R
N310	D
S311	G,N

**EP 2 357 227 B1**

(continued)

5  
10  
15  
20  
25  
30  
35

Position	Preferred Exchange
N318	Y
D320	V,E,N
T335	I
T344	M
D346	G,A,E,V
Q349	R,K
A358	E
Y374	C,P,R,H,S,A
A375	C,D,N,Y,R,Q,L,V,E,G,T,M
T392	C,D,K
T393	A
D410	G
Y422	F
P442	S,del
N445	D
R446	S,G
T456	T,A
S460	L,P
P462	L,del
G463	D
H468	L,Q,R
V482	A,I

7. The polypeptide according to one or more of the preceding claims, wherein the polypeptide has an amino acid sequence selected from the list of the following mutations of SEQ ID NO: 2:

40  
45  
50  
55

75	Q1L,G4C,A72C,Q349K
88	Q1L,G4C,A72C,S86T,Q349R
89	Q1L,G4C,A72C,D181N,Q349R
90	Q1L,G4C,A72C,E183K,Q349R
91	Q1L,G4C,A72C,D181N,E183K,Q349R
92	Q1L,G4C,A72C,D320V,Q349R
93	Q1L,G4C,A72C,S86T,D181N,E183K,D320V,Q349R
98	Q1L,G4C,A72C,Q349R
148	Q1L,G4C,A72C,Q349K,T392M
153	Q1L,G4C,A68T,A72C,Q349K,G439D,R453S
154	Q1L,G4C,A72C,D202N,Q349K
155	Q1L,G4C,A68T,A72C,Q349K

**EP 2 357 227 B1**

(continued)

5	156	Q1L,G4C,A72C,K154R,Q349K,T393I
	157	Q1L,G4C,A72C,S193P,Q349K,V482I
	158	Q1L,G4C,A72C,H203R,Q349K,P442S
	159	Q1L,G4C,A72C,Q349K,H468R
10	160	Q1L,G4C,A72C,D202N,Q349K,G486D
	161	Q1L,G4C,E65K,A72C,Q349K
	162	Q1L,G4C,A72C,Q349K,Y422F
	163	Q1L,G4C,Q28R,A72C,Q349K,H468L
15	164	Q1L,G4C,A72C,D181N,D247N,Q349K
	165	Q1L,G4C,A72C,D181N,Q349K,T451S
	166	Q1L,G4C,Q28R,A72C,Q349K
20	167	Q1L,G4C,A72C,A145T,H203R,Q349K,T403K
	168	Q1L,G4C,A72C,1200F,Q349K,L500I
	169	Q1L,G4C,D64N,A72C,Q349K
	170	Q1L,G4C,A72C,V152A,Q349K
25	171	Q1L,G4C,T15S,A72C,Y244F,Q349K
	172	Q1L,G4C,A6V,A72C,Q349K
	173	Q1L,G4C,A72C,S311N,Q349K,G463D
	174	Q1L,G4C,A72C,Y155C,Q349K
30	175	Q1L,G4C,A72C,S311N,Q349K
	176	Q1L,G4C,A72C,D346V,Q349K
	177	Q1L,G4C,A72C,Q349K,T392K
35	178	Q1L,G4C,A72C,S311G,Q349K
	179	Q1L,G4C,A72C,S311G,Q349K,H468R

- 40 **8.** The polypeptide according to one or more of the preceding claims, which is expressed and secreted at a level of more than 100 mg/l, more preferably of more than 200 mg/l, particularly preferably of more than 500 mg/l, and most preferably of more than 1 g/l into the supernatant after introduction of a nucleic acid encoding a polypeptide having an amino acid sequence with at least 85% sequence identity to the SEQ ID NO: 2 into a yeast, wherein the amino acid residue at position Q1 of SEQ ID NO 2 must be modified by substitution or deletion.
- 45 **9.** A nucleic acid encoding the polypeptide of one or more of claim 1 to 8, preferably having at least 95% identity to SEQ ID NO: 1.
- 10.** A vector comprising the nucleic acid of claim 9.
- 50 **11.** A host cell transformed with a vector of claim 10.
- 12.** The host cell of claim 11, wherein the host cell is derived from the group consisting of Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia, Pichia, Hansenula, Aspergillus, Trichoderma, Penicillium, Candida and Yarrowia.
- 55 **13.** Composition comprising the polypeptide of one or more of claims 1 to 9 and one or more endoglucanases and/or one or more beta-glucosidases and/or one or more further cellobiohydrolases and/or one or more xylanases.

14. Use of the polypeptide according to one or more of claims 1 to 9 or of the composition of claim 13 for the enzymatic degradation of lignocellulosic biomass, and/or for textiles processing and/or as ingredient in detergents and/or as ingredient in food or feed compositions.

5

**Patentansprüche**

1. Polypeptid mit Cellobiohydrolaseaktivität, wobei das Polypeptid eine Aminosäuresequenz mit mindestens 85% Sequenzidentität zu SEQ ID NO: 2 umfasst, wobei der Aminosäurerest in Position Q1 von SEQ ID NO: 2 durch Substitution oder Deletion modifiziert ist.
2. Polypeptid nach Anspruch 1, wobei das Polypeptid 50% seiner maximalen Stoffwandlungsleistung beibehält, wenn die Umwandlung 60 Minuten lang bei einer Temperatur von 60°C oder höher erfolgt.
3. Polypeptid nach Anspruch 1 oder 2, wobei das Polypeptid eine Aminosäuresequenz mit mindestens 90%, vorzugsweise mindestens 95%, stärker bevorzugt mindestens 99% Sequenzidentität zu SEQ ID NO: 2 umfasst.
4. Polypeptid nach einem oder mehreren der vorhergehenden Ansprüche, wobei die Aminosäuresequenz des Polypeptids die Sequenz gemäß SEQ ID NO: 2 oder eine Sequenz gemäß SEQ ID NO: 2, wobei 1 bis 75 Aminosäurereste, stärker bevorzugt 1 bis 35 Aminosäurereste, substituiert, deletiert oder insertiert sind, aufweist.
5. Polypeptid nach Anspruch 4, wobei zusätzlich einer oder mehrere der folgenden Aminosäurereste in der Sequenz gemäß SEQ ID NO: 2 durch Substitution oder Deletion modifiziert sind: die Positionen G4, A6, T15, Q28, W40, D64, E65, A72, S86, K92, V130, V152, Y155, K159, D181, E183, N194, D202, P224, T243, Y244, 1277, K304, N310, S311, N318, D320, T335, T344, D346, Q349, A358, Y374, A375, T392, T393, D410, Y422, P442, N445, R446, T456, S460, P462, G463, H468 und/oder V482 der Aminosäuren 1 bis 500 von SEQ ID NO: 2.
6. Polypeptid nach Anspruch 5, wobei das Polypeptid einen oder mehrere der folgenden bevorzugten Austausche in Bezug auf die Sequenz gemäß SEQ ID NO: 2 umfasst:

10

15

20

25

30

Position	Bevorzugter Austausch
Q1	L
G4	C
A6	G, V
T15	S
Q28	Q, R
W40	R
D64	N
E65	K, V
A72	C, V
S86	T
K92	K, R
V130	I, V
V152	A, E
Y155	C
K159	E
D181	N
E183	V, K

35

40

45

50

55

**EP 2 357 227 B1**

(fortgesetzt)

Position	Bevorzugter Austausch
5	N194 C, R, Y, D, K, I, L, G, Q, S, V
	D202 Y, N, G
	P224 L
	T243 I, C, R, Y, A, F, Q, P, D, V, W, L, M
10	Y244 F, H
	1277 V
	K304 R
15	N310 D
	S311 G, N
	N318 Y
	D320 V, E, N
20	T335 I
	T344 M
	D346 G, A, E, V
25	Q349 R, K
	A358 E
	Y374 C, P, R, H, S, A
	A375 C, D, N, Y, R, Q, L, V, E, G, T, M
30	T392 C, D, K
	T393 A
	D410 G
35	Y422 F
	P442 S, del
	N445 D
	R446 S, G
40	T456 T, A
	S460 L, P
	P462 L, del
45	G463 D
	H468 L, Q, R
	V482 A, I

50 **7.** Polypeptid nach einem oder mehreren der vorhergehenden Ansprüche, wobei das Polypeptid eine Aminosäuresequenz, ausgewählt aus der Liste der folgenden Mutationen von SEQ ID NO: 2, aufweist:

55	75	Q1L, G4C, A72C, Q349K
	88	Q1L, G4C, A72C, S86T, Q349R
	89	Q1L, G4C, A72C, D181N, Q349R

## EP 2 357 227 B1

(fortgesetzt)

5	90	Q1L, G4C, A72C, E183K, Q349R
	91	Q1L, G4C, A72C, D181N, E183K, Q349R
	92	Q1L, G4C, A72C, D320V, Q349R
	93	Q1L, G4C, A72C, S86T, D181N, E183K, D320V, Q349R
10	98	Q1L, G4C, A72C, Q349R
	148	Q1L, G4C, A72C, Q349K, T392M
	153	Q1L, G4C, A68T, A72C, Q349K, G439D, R453S
	154	Q1L, G4C, A72C, D202N, Q349K
15	155	Q1L, G4C, A68T, A72C, Q349K
	156	Q1L, G4C, A72C, K154R, Q349K, T3a3I
	157	Q1L, G4C, A72C, S193P, Q349K, V482I
	158	Q1L, G4C, A72C, H203R, Q349K, P442S
20	159	Q1L, G4C, A72C, Q349K, H468R
	160	Q1L, G4C, A72C, D202N, Q349K, G486D
	161	Q1L, G4C, E65K, A72C, Q349K
25	162	Q1L, G4C, A72C, Q349K, Y422F
	163	Q1L, G4C, Q28R, A72C, Q349K, H468L
	164	Q1L, G4C, A72C, D181N, D247N, Q349K
	165	Q1L, G4C, A72C, D181N, Q349K, T451S
30	166	Q1L, G4C, Q28R, A72C, Q349K
	167	Q1L, G4C, A72C, A145T, H203R, Q349K, T403K
	168	Q1L, G4C, A72C, I200F, Q349K, L500I
35	169	Q1L, G4C, D64N, A72C, Q349K
	170	Q1L, G4C, A72C, V152A, Q349K
	171	Q1L, G4C, T15S, A72C, Y244F, Q349K
40	172	Q1L, G4C, A6V, A72C, Q349K
	173	Q1L, G4C, A72C, S311N, Q349K, G463D
	174	Q1L, G4C, A72C, Y155C, Q349K
	175	Q1L, G4C, A72C, S311N, Q349K
45	176	Q1L, G4C, A72C, D346V, Q349K
	177	Q1L, G4C, A72C, Q349K, T392K
	178	Q1L, G4C, A72C, S311G, Q349K
50	179	Q1L, G4C, A72C, S311G, Q349K, H468R

8. Polypeptid nach einem oder mehreren der vorhergehenden Ansprüche, das nach dem Einführen einer Nukleinsäure, die für ein Polypeptid mit einer Aminosäuresequenz mit mindestens 85% Sequenzidentität zu der SEQ ID NO: 2 in eine Hefe, wobei der Aminosäurerest in Position Q1 von SEQ ID NO: 2 durch Substitution oder Deletion modifiziert sein muss, auf einem Niveau von mehr als 100 mg/l, stärker bevorzugt mehr als 200 mg/l, besonders bevorzugt mehr als 500 mg/l und am stärksten bevorzugt mehr als 1 g/l exprimiert und in den Überstand sezerniert wird.

9. Nukleinsäure, die für das Polypeptid nach einem oder mehreren der Ansprüche 1 bis 8 codiert, vorzugsweise mit

## EP 2 357 227 B1

mindestens 95% Identität zu SEQ ID NO: 1.

10. Vektor, der die Nukleinsäure nach Anspruch 9 umfasst.

5 11. Wirtszelle, die mit einem Vektor nach Anspruch 10 transformiert ist.

12. Wirtszelle nach Anspruch 11, wobei die Wirtszelle von der Gruppe bestehend aus Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia, Hansenula, Aspergillus, Trichoderma, Penicillium, Candida und Yarrowina abgeleitet ist.

10

13. Zusammensetzung, umfassend das Polypeptid nach einem oder mehreren der Ansprüche 1 bis 9 und eine oder mehrere Endoglucanasen und/oder eine oder mehrere beta-Glucosidasen und/oder eine oder mehrere weitere Cellobiohydrolasen und/oder eine oder mehrere Xylanasen.

15

14. Verwendung des Polypeptids nach einem oder mehreren der Ansprüche 1 bis 9 oder der Zusammensetzung nach Anspruch 13 für den enzymatischen Abbau von Lignocellulosebiomasse und/oder für die Textilverarbeitung und/oder als Bestandteil in Detergenzien und/oder als Bestandteil in Nahrungs- oder Futtermittelzusammensetzungen.

20

### Revendications

1. Polypeptide ayant une activité de cello-biohydrolase, dans laquelle le polypeptide comprend une séquence d'acides aminés ayant une identité de séquence, d'au moins 85%, avec la SEQ ID n° : 2, dans lequel le résidu d'acide aminé en position Q1 de la SEQ ID n° : 2 est modifié par substitution ou délétion.

25

2. Polypeptide selon la revendication 1, dans laquelle le polypeptide conserve 50% de sa capacité maximale de conversion du substrat quand la conversion est faite pendant 60 minutes à une température de 60°C ou plus.

30

3. Polypeptide selon la revendication 1 ou la 2, dans laquelle le polypeptide comprend une séquence d'acides aminés ayant une identité de séquence d'au moins 90%, de préférence d'au moins 95%, mieux préféré d'au moins 99%, avec la SEQ ID n° : 2.

35

4. Polypeptide selon une ou plusieurs des revendications précédentes, dans laquelle la séquence d'acides aminés du polypeptide a la séquence définie par la SEQ ID n° : 2 ou une séquence telle que définie par la SEQ ID n° : 2, dans laquelle de 1 à 75 résidu(s) d'acide(s) aminé(s), mieux préféré de 1 à 35 résidu(s) d'acide(s) aminé(s) est (sont) substitué(s), supprimé(s) ou inséré(s).

40

5. Polypeptide selon la revendication 4, dans laquelle en outre un ou plusieurs des résidus d'acides aminés suivants de la séquence définie par la SEQ ID n° : 2 est (sont) modifié(s) par substitution ou délétion : positions G4, A6, T15, Q28, W40, D64, E65, A72, S86, K92, V130, V152, Y155, K159, D181, E183, N194, D202, P224, T243, Y244, I277, K304, N310, S311, N318, D320, T335, T344, D346, Q349, A358, Y374, A375, T392, T393, D410, Y422, P442, N445, R446, T456, S460, P462, G463, H468 et/ou V482 des acides aminés 1 à 500 de la SEQ ID n° : 2.

45

6. Polypeptide selon la revendication 5, dans laquelle le polypeptide comprend un ou plusieurs des échanges préférés suivants en ce qui concerne la séquence définie par la SEQ ID n° : 2 :

50

55

Position	Échange préféré
Q1	L
G4	C
A6	G,V
T15	S
Q28	Q,R
W40	R

EP 2 357 227 B1

(suite)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Position	Échange préféré
D64	N
E65	K,V
A72	C,V
S86	T
K92	K,R
V130	I,V
V152	A,E
Y155	C
K159	E
D181	N
E183	V,K
N194	C,R,Y,D,K,I,L,G,Q,S,V
D202	Y,N,G
P224	L
T243	I,C,R,Y,A,F,Q,P,D,V,W,L,M
Y244	F,H
I277	V
K304	R
N310	D
S311	G,N
N318	Y
D320	V,E,N
T335	I
T344	M
D346	G,A,E,V
Q349	R,K
A358	E
Y374	C,P,R,H,S,A
A375	C,D,N,Y,R,Q,L,V,E,G,T,M
T392	C,D,K
T393	A
D410	G
Y422	F
P442	S,del
N445	D
R446	S,G
T456	T,A
S460	L,P

**EP 2 357 227 B1**

(suite)

Position	Échange préféré
P462	L,del
G463	D
H468	L,Q,R
V482	A,I

7. Polypeptide selon une ou plusieurs des revendications précédentes, dans laquelle le polypeptide a une séquence d'acides aminés choisie dans la liste des mutations suivantes de la SEQ ID n° : 2 :

75	Q1L,G4C,A72C,Q349K
88	Q1L,G4C,A72C,S86T,Q349R
89	Q1L,G4C,A72C,D181N,Q349R
90	Q1L,G4C,A72C,E183K,Q349R
91	Q1L,G4C,A72C,D181N,E183K,Q349R
92	Q1L,G4C,A72C,D320V,Q349R
93	Q1L,G4C,A72C,S86T,D181N,E183K,D320V,Q349R
98	Q1L,G4C,A72C,Q349R
148	Q1L,G4C,A72C,Q349K,T392M
153	Q1L,G4C,A68T,A72C,Q349K,G439D,R453S
154	Q1L,G4C,A72C,D202N,Q349K
155	Q1L,G4C,A68T,A72C,Q349K
156	Q1L,G4C,A72C,K154R,Q349K,T393I
157	Q1L,G4C,A72C,S193P,Q349K,V482I
158	Q1L,G4C,A72C,H203R,Q349K,P442S
159	Q1L,G4C,A72C,Q349K,H468R
160	Q1L,G4C,A72C,D202N,Q349K,G486D
161	Q1L,G4C,E65K,A72C,Q349K
162	Q1L,G4C,A72C,Q349K,Y422F
163	Q1L,G4C,Q28R,A72C,Q349K,H468L
164	Q1L,G4C,A72C,D181N,D247N,Q349K
165	Q1L,G4C,A72C,D181N,Q349K,T451S
166	Q1L,G4C,Q28R,A72C,Q349K
167	Q1L,G4C,A72C,A145T,H203R,Q349K,T403K
168	Q1L,G4C,A72C,I200F,Q349K,L500I
169	Q1L,G4C,D64N,A72C,Q349K
170	Q1L,G4C,A72C,V152A,Q349K
171	Q1L,G4C,T15S,A72C,Y244F,Q349K
172	Q1L,G4C,A6V,A72C,Q349K
173	Q1L,G4C,A72C,S311N,Q349K,G463D

## EP 2 357 227 B1

(suite)

174	Q1L,G4C,A72C,Y155C,Q349K
175	Q1L,G4C,A72C,S311N,Q349K
176	Q1L,G4C,A72C,D346V,Q349K
177	Q1L,G4C,A72C,Q349K,T392K
178	Q1L,G4C,A72C,S311G,Q349K
179	Q1L,G4C,A72C,S311G,Q349K,H468R

5

10

15

20

25

30

35

40

45

50

55

8. Polypeptide, selon une ou plusieurs des revendications précédentes, qui est exprimé et sécrété à un taux supérieur à 100 mg/l, mieux préféré supérieur à 200 mg/l, particulièrement préféré supérieur à 500 mg/l et, de manière préférée entre toutes, supérieur à 1 g/l dans le surnageant après l'introduction d'un acide nucléique, qui code pour un polypeptide ayant une séquence d'acides aminés avec une identité de séquence d'au moins 85% avec la SEQ ID n° : 2, dans une levure, dans laquelle le résidu d'acide aminé en position Q1 de la SEQ ID n° : 2 doit être modifié par substitution ou délétion.
9. Acide nucléique codant pour le polypeptide, selon une ou plusieurs des revendications 1 à 8, ayant de préférence une identité d'au moins 95% avec la SEQ ID n° : 1.
10. Vecteur comprenant l'acide nucléique selon la revendication 9.
11. Cellule hôte transformée avec un vecteur selon la revendication 10.
12. Cellule hôte selon la revendication 11, dans laquelle la cellule hôte est dérivée du groupe constitué par Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia, Hansenula, Aspergillus, Trichoderma, Penicillium, Candida et Yarrowina.
13. Composition comprenant le polypeptide, selon une ou plusieurs des revendications 1 à 9, et une ou plusieurs endoglucanase(s) et/ou une ou plusieurs bêta-glucosidase(s) et/ou une ou plusieurs cello-biohydrolase(s) en outre et/ou une ou plusieurs xylanase(s).
14. Utilisation du polypeptide, selon une ou plusieurs des revendications 1 à 9, ou de la composition, selon la revendication 13, pour la dégradation enzymatique d'une biomasse ligno-cellulosique, et/ou pour le traitement de textiles et/ou comme ingrédient dans les détergents et/ou comme ingrédient dans de la nourriture ou des compositions alimentaires.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10

	1					50
T._reesei_CBHI	QSACTLQSET	HPPLTWQKCS	SGGTCTQQTG	SVVIDANWRW	THATNSSTNC	
SeqID_NO.2	QQAGTATAEN	HPPLTWQECT	APGSCTTQNG	AVVLDANWRW	VHDVNGYTNC	
	51					100
T._reesei_CBHI	YDGNTWSSTL	CPDNETCAKN	CCLDGAAYAS	TYGVTTSGNS	LSIGFVTQSA	
SeqID_NO.2	YTGNTWDPTY	CPDDETCAQN	CALDGADYEG	TYGVTTSSGSS	LKLNFTVTG..	
	101					150
T._reesei_CBHI	QKNVGARLYL	MASDTTYQEF	TLIGNEFSFD	VDVSQLPCGL	NGALYFVSMO	
SeqID_NO.2	.SNVGSRLYL	LQDDSTYQIF	KLLNREFSFD	VDVSNLPCGL	NGALYFVAMD	
	151					200
T._reesei_CBHI	ADGGVSKYPT	NTAGAKYGTG	YCDSQCPRDL	KFINGQANVE	GWEPSSNNAN	
SeqID_NO.2	ADGGVSKYPN	NKAGAKYGTG	YCDSQCPRDL	KFIDGEANVE	GWQPSSNNAN	
	201					250
T._reesei_CBHI	TGIGGHGSCC	SEMEDIWEANS	ISEALTPHPC	TTVGQEICEG	DGCGGTYSDN	
SeqID_NO.2	TGIGDHGSCC	AEMDVWEANS	ISNAVTPHPC	DTPGQTMCSG	DDCGGTYSDN	
	251					300
T._reesei_CBHI	RYGGTCDDPDG	CDWNPYRLGN	TSFYGPGSSF	TLDTTKKLTV	VTQFETSG..	
SeqID_NO.2	RYAGTCDDPDG	CDFNPYRMGN	TSFYGPGK..	IIDTTKPFTV	VTQFLTDDGT	
	301					350
T._reesei_CBHI	.....AINR	YYVQNGVTFQ	QPNAELGSYS	GNELNDDYCT	ABEAFFGGSS	
SeqID_NO.2	DTGTLSEIKR	FYIQNSNVIP	QPNSDISGVT	GNSITTEFCT	AQKQAFGDTD	
	351					400
T._reesei_CBHI	.FSDKGGLTQ	FKKATSGGMV	LVMSLWDDYY	ANMLWLDSTY	PTNETSSTPG	
SeqID_NO.2	DFSQHGGLAK	MGAAMQGMV	LVMSLWDDYA	AQMLWLDSDY	PTDADPTTPG	
	401					450
T._reesei_CBHI	AVRGSCSTSS	GVPAQVESQS	PNAKVTFSNI	KFGPIGSTGN	PSGGNPPGGN	
SeqID_NO.2	IARGTCPTDS	GVPSDVESQS	PNSYVTYSNI	KFGPIGSTGN	PSGGNPPGGN	
	451					500
T._reesei_CBHI	RGTTTTTRPA	TTTGSSPGPT	QSHYGQCGGI	GYSGPTVCAS	GTTCQVLNPN	
SeqID_NO.2	RGTTTTTRPA	TTTGSSPGPT	QSHYGQCGGI	GYSGPTVCAS	GTTCQVLNPN	
	501					
T._reesei_CBHI	YSQCL					
SeqID_NO.2	YSQCL					

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- US 7459299 B2 [0007]
- US 7452707 B2 [0007]
- WO 2005030926 A [0007]
- WO 0104284 A1 [0007]
- US 20090162916 A1 [0007]
- WO 03000941 A [0010]
- US 2009042266 A [0011]
- US 5686593 A [0012]
- CN 01757710 [0019]
- WO 2009138877 A [0022]
- WO 2009139839 A [0023]

## Non-patent literature cited in the description

- **LYND LR ; WEIMER PJ ; VAN ZYL WH ; PRETORIUS IS.** Microbial cellulose utilization: fundamentals and biotechnology. *Microbiol Mol Biol Rev*, September 2002, vol. 66 (3), 506-77 [0004]
- **KURABI A ; BERLIN A ; GILKES N ; KILBURN D ; BURA R ; ROBINSON J ; MARKOV A ; SKOMAROVSKY A ; GUSAKOV A ; OKUNEV O.** Enzymatic hydrolysis of steam-exploded and ethanol organosolv-pretreated Douglas-Fir by novel and commercial fungal cellulases. *Appl Biochem Biotechnol.*, 2005, vol. 121-124, 219-30 [0006]
- **GRASSICK A ; MURRAY PG ; THOMPSON R ; COLLINS CM ; BYRNES L ; BIRrane G ; HIGGINS TM ; TUOHY MG.** Three-dimensional structure of a thermostable native cellobiohydrolase, CBH IB, and molecular characterization of the cel7 gene from the filamentous fungus, *Talaromyces emersonii*. *Eur J Biochem*, November 2004, vol. 271 (22), 4495-4506 [0007]
- **VOUTILAINEN SP ; MURRAY PG ; TUOHY MG ; KOIVULA A.** Expression of *Talaromyces emersonii* cellobiohydrolase Cel7A in *Saccharomyces cerevisiae* and rational mutagenesis to improve its thermostability and activity. *Protein Eng Des Sel.*, February 2010, vol. 23 (2), 69-79 [0007]
- **PERCIVAL ZHANG YH ; HIMMEL ME ; MIELENZ JR.** Outlook for cellulase improvement: screening and selection strategies. *Biotechnol Adv.*, September 2006, vol. 24 (5), 452-81 [0008]
- **PENTTILÄ ME ; ANDRÉ L ; LEHTOVAARAP ; BAILEY M ; TEERI TT ; KNOWLES JK.** Efficient secretion of two fungal cellobiohydrolases by *Saccharomyces cerevisiae*. *Gene*, 1988, vol. 63 (1), 103-12 [0009]
- **HONG J ; TAMAKI H ; YAMAMOTO K ; KUMAGAI H.** Cloning of a gene encoding thermostable cellobiohydrolase from *Thermoascus aurantiacus* and its expression in yeast. *Appl Microbiol Biotechnol.*, November 2003, vol. 63 (1), 42-50 [0013]
- **TUOHY MG ; WALSH DJ ; MURRAY PG ; CLAEYSSENS M ; CUFFE MM ; SAVAGE AV ; COUGHLAN MP.** Kinetic parameters and mode of action of the cellobiohydrolases produced by *Talaromyces emersonii*. *Biochim Biophys Acta*, 29 April 2002, vol. 1596 (2), 366-80 [0014]
- **NEVOIGT E.** Progress in metabolic engineering of *Saccharomyces cerevisiae*. *Microbiol Mol Biol Rev.*, September 2008, vol. 72 (3), 379-412 [0015]
- **FUJITA Y ; ITO J ; UEDA M ; FUKUDA H ; KONDO A.** Synergistic saccharification, and direct fermentation to ethanol, of amorphous cellulose by use of an engineered yeast strain codisplaying three types of cellulolytic enzyme. *Appl Environ Microbiol.*, February 2004, vol. 70 (2), 1207-12 [0016]
- **BOER H ; TEERI TT ; KOIVULA A.** Characterization of *Trichoderma reesei* cellobiohydrolase Cel7A secreted from *Pichia pastoris* using two different promoters. *Biotechnol Bioeng.*, 05 September 2000, vol. 69 (5), 486-94 [0017]
- **GODBOLE S ; DECKER SR ; NIEVES RA ; ADNEY WS ; VINZANT TB ; BAKER JO ; THOMAS SR ; HIMMEL ME.** Cloning and expression of *Trichoderma reesei* cellobiohydrolase I in *Pichia pastoris*. *Biotechnol Prog.*, September 1999, vol. 15 (5), 828-33 [0018]
- **KANOKRATANA P ; CHANTASINGH D ; CHAMPREDA V ; TANAPONGPIPAT S ; POOTANAKIT K ; EURWILAICHITR L.** Identification and expression of cellobiohydrolase (CBHI) gene from an endophytic fungus, *Fusicoccum* sp. (BCC4124) in *Pichia pastoris*. *LProtein Expr Purif.*, 19 September 2007, vol. 58 (1), 148-53 [0019]
- **LI YL ; LI H ; LI AN ; LI DC.** Cloning of a gene encoding thermostable cellobiohydrolase from the thermophilic fungus *Chaetomium thermophilum* and its expression in *Pichia pastoris*. *J Appl Microbiol.*, June 2009, vol. 106 (6), 1867-75 [0019]

- **VOUTILAINEN SP ; PURANEN T ; SIIKA-AHO M ; LAPPALAINEN A ; ALAPURANEN M ; KALLIO J ; HOOMAN S ; VIKARI L ; VEHEMAANPERÄ J ; KOIVULA A.** Cloning, expression, and characterization of novel thermostable family 7 cellobiohydrolases. *Biotechnol Bioeng.*, 15 October 2008, vol. 101 (3), 515-28 [0020]
- **VIKARI L ; ALAPURANEN M ; PURANEN T ; VEHEMAANPERÄ J ; SIIKA-AHO M.** Thermostable enzymes in lignocellulose hydrolysis. *Adv Biochem Eng Biotechnol.*, 2007, vol. 108, 121-45 [0020]
- **GRASSICK A ; MURRAY PG ; THOMPSON R ; COLLINS CM ; BYRNES L ; BIRANEG ; HIGGINS TM ; TUOHY MG.** Three-dimensional structure of a thermostable native cellobiohydrolase, CBH IB, and molecular characterization of the cel7 gene from the filamentous fungus, *Talaromyces emersonii*. *Eur J Biochem*, November 2004, vol. 271 (22), 4495-506 [0021]
- **LARKIN M.A. ; BLACKSHIELDS G. ; BROWN N.P. ; CHENNA R. ; MCGETTIGAN P.A. ; MCWILLIAM H. ; VALENTIN F. ; WALLACE I.M. ; WILM A. ; LOPEZ R.** ClustalW and ClustalX version 2. *Bioinformatics*, 2007, vol. 23 (21), 2947-2948 [0039]
- **LIVINGSTONE CD ; BARTON GJ.** Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation. *Comput. Appl Biosci.*, 1993, vol. 9, 745-756 [0045]
- **TAYLOR W. R.** The classification of amino acid conservation. *J.Theor.Biol.*, 1986, vol. 119, 205-218 [0045]
- **WATERHAM, H. R. ; DIGAN, M. E. ; KOUTZ, P. J. ; LAIR, S. V. ; CREGG, J. M.** Isolation of the *Pichia pastoris* glyceraldehyde-3-phosphate dehydrogenase gene and regulation and use of its promoter. *Gene*, 1997, vol. 186, 37-44 [0076]
- **CREGG, J.M.** *Pichia* Protocols in Methods in Molecular Biology. Humana Press, 2007 [0076]
- **R.CRAIG CADWELL ; G.F. JOYCE.** Mutagenic PCR, in PCR Primer: a laboratory manual. Cold Spring Harbor Press, 1995, 583-589 [0084]

Optimalizált cellulóz enzimek

Szabadalmi igénypontok:

1. Cellobiohidroláz-aktivitással rendelkező polipeptid, amely a SEQ ID NO:2 szerinti szekvenciával legalább 85 %-os azonosságot mutató aminosav-szekvenciát tartalmaz, ahol a SEQ ID NO:2 Q1 helyzeténél levő aminosav-maradék helyettesítéssel vagy törléssel módosítva van.
2. Az 1. igénypont szerinti polipeptid, ahol a polipeptidnek a maximális szubsztrát-konverziós kapacitása 50 %-ban megmarad, amikor a konverzió 60 percig 60 °C-on vagy ennél magasabb hőmérsékleten történik.
3. Az 1. vagy 2. igénypont szerinti polipeptid, ahol a peptid a SEQ ID NO:2 szerinti szekvenciával legalább 90 %-os, előnyösen legalább 95 %-os, még előnyösebben legalább 99 %-os azonosságot mutató aminosav-szekvenciát tartalmaz.
4. Az előző igénypontok közül egy vagy több szerinti polipeptid, ahol a polipeptid a SEQ ID NO:2 által definiált aminosav-szekvenciával, vagy pedig egy a SEQ ID NO:2 által definiált olyan aminosav-szekvenciával rendelkezik, ahol 1–75 aminosav-maradék, előnyösebben 1–35 aminosav-maradék van helyettesítve, törölve vagy beiktatva.
5. A 4. igénypont szerinti polipeptid, ahol még a SEQ ID NO:2 által definiált szekvencia következő aminosav-maradéka közül egy vagy több helyettesítéssel vagy törléssel van módosítva: G4, A6, T15, Q28, W40, D64, E65, A72, S86, K92, V130, V152, Y155, K159, D181, E183, N194, D202, P224, T243, Y244, I277, K304, N310, S311, N318, D320, T335, T344, D346, Q349, A358, Y374, A375, T392, T393, D410, Y422, P442, N445, R446, T456, S460, P462, G463, H468 és/vagy V482 helyzetekben levő 1–500. aminosav a SEQ ID NO:2-ben.

6. Az 5. igénypont szerinti polipeptid, ahol a polipeptid a következő előnyös cserék közül egyet vagy többet tartalmaz a SEQ ID NO:2 által definiált szekvenciához képest:

Helyzet	Előnyös csere
Q1	L
G4	C
A6	G,V
T15	S
Q28	Q,R
W40	R
D64	N
E65	K,V
A72	C,V
S86	T
K92	K,R
V130	I,V
V152	A,E
Y155	C
K159	E
D181	N
E183	V,K
N194	C,R,Y,D,K,I,L,G,Q,S,V
D202	Y,N,G
P224	L
T243	I,C,R,Y,A,F,Q,P,D,V,W,L,M
Y244	F,H
I277	V
K304	R
N310	D
S311	G,N
N318	Y
D320	V,E,N
T335	I

Helyzet	Előnyös csere
T344	M
D346	G,A,E,V
Q349	R,K
A358	E
Y374	C,P,R,H,S,A
A375	C,D,N,Y,R,Q,L,V,E,G,T,M
T392	C,D,K
T393	A
D410	G
Y422	F
P442	S,del
N445	D
R446	S,G
T456	T,A
S460	L,P
P462	L,del
G463	D
H468	L,Q,R
V482	A,I

7. Az előző igénypontok közül egy vagy több szerinti polipeptid, ahol a polipeptid a SEQ ID NO:2 alábbi mutációit tartalmazó felsorolásból választott aminosav-szekvenciával rendelkezik:

75	Q1L,G4C,A72C,Q349K
88	Q1L,G4C,A72C,S86T,Q349R
89	Q1L,G4C,A72C,D181N,Q349R
90	Q1L,G4C,A72C,E183K,Q349R
91	Q1L,G4C,A72C,D181N,E183K,Q349R
92	Q1L,G4C,A72C,D320V,Q349R
93	Q1L,G4C,A72C,S86T,D181N,E183K,D320V,Q349R
98	Q1L,G4C,A72C,Q349R
148	Q1L,G4C,A72C,Q349K,T392M

153	Q1L,G4C,A68T,A72C,Q349K,G439D,R453S
154	Q1L,G4C,A72C,D202N,Q349K
155	Q1L,G4C,A68T,A72C,Q349K
156	Q1L,G4C,A72C,K154R,Q349K,T393I
157	Q1L,G4C,A72C,S193P,Q349K,V482I
158	Q1L,G4C,A72C,H203R,Q349K,P442S
159	Q1L,G4C,A72C,Q349K,H468R
160	Q1L,G4C,A72C,D202N,Q349K,G486D
161	Q1L,G4C,E65K,A72C,Q349K
162	Q1L,G4C,A72C,Q349K,Y422F
163	Q1L,G4C,Q28R,A72C,Q349K,H468L
164	Q1L,G4C,A72C,D181N,D247N,Q349K
165	Q1L,G4C,A72C,D181N,Q349K,T451S
166	Q1L,G4C,Q28R,A72C,Q349K
167	Q1L,G4C,A72C,A145T,H203R,Q349K,T403K
168	Q1L,G4C,A72C,I200F,Q349K,L500I
169	Q1L,G4C,D64N,A72C,Q349K
170	Q1L,G4C,A72C,V152A,Q349K
171	Q1L,G4C,T15S,A72C,Y244F,Q349K
172	Q1L,G4C,A6V,A72C,Q349K
173	Q1L,G4C,A72C,S311N,Q349K,G463D
174	Q1L,G4C,A72C,Y155C,Q349K
175	Q1L,G4C,A72C,S311N,Q349K
176	Q1L,G4C,A72C,D346V,Q349K
177	Q1L,G4C,A72C,Q349K,T392K
178	Q1L,G4C,A72C,S311G,Q349K
179	Q1L,G4C,A72C,S311G,Q349K,H468R

8. Az előző igénypontok közül egy vagy több szerinti polipeptid, amely 100 mg/l értéknél magasabb szinten, előnyösebben 200 mg/l értéknél magasabb szinten, különösen előnyösen 500 mg/l értéknél magasabb szinten, és legelőnyösebben 1 g/l értéknél magasabb szinten expresszálódik és szekretálódik a felülúszóba, miután egy élesztőbe olyan nukleinsavat iktattunk

be, amely egy a SEQ ID NO:2 szerinti szekvenciával legalább 85 %-ban azonos aminosav-szekvenciával rendelkező polipeptidet kódol, ahol a SEQ ID NO:2 Q1 helyzetében levő aminosav-maradékot helyettesítéssel vagy törléssel módosítani kell.

9. Nukleinsav, amely az 1-8. igénypontok közül egy vagy több szerinti, a SEQ ID NO:1 szerinti szekvenciával legalább 95 %-ban azonos polipeptidet kódol.
10. Vektor, amely a 9. igénypont szerinti nukleinsavat tartalmazza.
11. Gazdasejt, amely egy 10. igénypont szerinti vektorral van transzformálva.
12. A 11. igénypont szerinti gazdasejt, ahol a gazdasejt a következők által alkotott csoportból van származtatva: Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia, Pichia, Hansenula, Aspergillus, Trichoderma, Penicillium, Candida és Yarrowina.
13. Kompozíció, amely az 1-9. igénypontok közül egy vagy több szerinti polipeptidet és egy vagy több endoglukanázt és/vagy egy vagy több béta-gükozidázt és/vagy egy vagy több további cellobiohidrolázt és/vagy egy vagy több xilanázt tartalmaz.
14. Az 1-9. igénypontok közül egy vagy több szerinti polipeptid vagy a 13. igénypont szerinti kompozíció alkalmazása lignocellulóz biomaszra enzimatikus lebontásában és/vagy textílfeldolgozásban és/vagy komponensként detergensekben és/vagy komponensként élelmiszer- vagy takarmány-kompozíciókban.